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1. What is Osteosarcoma? 
Osteosarcoma is the most frequent high-grade primary malignant 
bone tumor that is thought to arise from mesenchymal stem cells 
with the capacity to produce osteoid.1,2 The overall incidence is of 
three cases per million annually. Osteosarcoma occurs 
predominantly in children and adolescents, and in people over 50 
years of age. It is located primarily in the metaphyseal region within 
the medullary cavity of long bones of the extremities (Fig. 1),2,3 
specifically in the knee area.4 Other locations are the pelvis, ribs 
and spine, which are associated with worse outcome.5,6  
Osteosarcoma is classified into various histological 
subtypes: conventional, telangiectatic, small cell and other rare types. Conventional 
osteosarcoma is the most frequent, which originates in the medullary cavity of the 
metaphyseal region of long bones, and is mainly high grade. Telangiectatic represent less 
than 4% of the osteosarcomas. It is similar to conventional osteosarcoma in terms of clinical 
presentation, treatment and prognosis.7 Small cell osteosarcoma is a rare entity with 1%-2% 
prevalence, and it resembles morphologically an Ewing sarcoma. However, small cell 
osteosarcoma has different genetic characteristics such as the absence of EWSR1 and FUS 
gene rearrangements, and the production of osteoid.8–10 
Osteosarcoma diagnosis is only confirmed by the 
presence of osteoid in the biopsy. However, these 
malignant cells also have the capacity to produce cartilage 
matrix or fibrous tissue, which divides osteosarcoma in 
three categories: osteoblastic, chondroblastic and 
fibroblastic. Usually, a tumor shows all three matrix types, 
making it difficult to categorize it. The tumor will fall into  
one of these categories when it presents more than 50% of 
one of the histological types.9 
 
2. Etiology 
2.1 Bone growth and turnover 
Figure 2. Primary osteosarcoma 
with osteoid (black arrow). 
Figure 1. Osteo-sarcoma 
of the distal femur 
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Adolescent growth spurt coincides with the peak onset of osteosarcoma: girls show an 
earlier peak than boys which could be caused by their earlier growth spurt.11 Research 
shows that there is higher incidence in boys (56%) compared to girls (42%).12–14  
2.2 Predispositions 
Paget’s disease is characterized by a metabolic bone disorder leading to increased and 
disorganized bone formation.15 It affects mainly people older than 50 years of age, and 
people with this disease present a 2% probability of developing osteosarcoma. Other 
predisposing factors are genetic disorders such as Li-Fraumeni syndrome, Rothmund-
Thomson syndrome and Beckman-Wiederman syndrome.11  
Li-Fraumeni syndrome is a hereditary disorder characterized by germline mutations 
in the TP53 gene. This syndrome is characterized by the occurrence of sarcomas, among 
other cancers, in persons under the age of 45 years old.16 These patients have a high risk of 
developing osteosarcoma. In fact, mice with p53R172H/+ mutation showed 2 times increase in 
number of osteosarcomas compared to p53+/- mice,17 and p53-null heterozygous mice 
present high numbers of osteosarcomas.18,19  
Rothmund-Thomson syndrome is an autosomal recessive genodermatosis 
characterized by poikiloderma, short stature, premature aging and skeletal abnormalities 
among other features. Patients with this rare disease have a predisposition to develop 
osteosarcoma.20,21 It was found that 60-65% of patients present mutations in the RECQL4 
helicase gene suggesting a possible role of this gene in osteosarcoma development.20 
Retinoblastoma is a hereditary disease that causes eye tumors in children. It is 
caused by mutations in RB1 gene. Osteosarcoma is the most common secondary tumor that 
arises in these patients.22,23  
Other rare genetic diseases such as Bloom, Werner, Rapadilino and Diamond 
blackfan are known for development of osteosarcoma among other malignancies.22  
Finally, osteosarcomas arise secondary to radiation affecting mainly older patients. 
Studies show that sarcomas associated with radiation are uncommon. However, 






3. Prognostic factors 
There are several clinical characteristics that are predictors of clinical outcome. The outcome 
for patients that at the moment of diagnosis present with metastasis is still poor, and no 
improvement was observed with chemotherapy.11,26,27 Additionally, the most common sites 
of recurrence are local and lung, presented in 20% and 62% of the cases respectively, and 
metastasis is correlated with poor survival.28,29 Another important prognostic factor is the 
tumor site. Several studies report that tumors located in the axial skeleton have particularly 
poor outcome.4–6,30 One of the requisites for a better control of the tumor is to achieve 
surgical excision with clean margins, and this is difficult for most of the axial tumors.11 
Response to chemotherapy is another variable that affects the outcome of these patients. 
Good responders are described as those with more than 90% of necrotic tissue after pre-
operative chemotherapy. Several studies show that there is a correlation between good 
response to chemotherapy and prognosis.31,32 Furthermore, tumor size is also considered a 
prognostic factor as indicated in a retrospective study of 331 osteosarcoma patients.33–35 
Finally, age is another prognostic factors. Older patients with osteosarcoma tend to have a 
worse prognosis than younger patients.4,36,37  
 
4. Tumor Biology 
Osteosarcoma cells are pleomorphic, anaplastic and hyperchromatic.38 They are also 
characterized by complex karyotype as a result of chromosomal abnormalities that are 
different from cell to cell and from tumor to tumor (Fig. 2).39,40 It was reported that copy 
number gains range from 7 to 190 and loses from 7 to 170 per sample. Gains are mainly 
located in chromosomes 6p, 8q/9p and 17p, and loses are in chromosomes 3q, 6q, 8p/9p, 
11p, 15q and 17q among other aberrations.41–43 These studies also show that genomic 
instability is correlated with poor prognosis and could be a cause of tumor initiation.44 The 
fact that there is abundant genetic instability in osteosarcoma, makes it difficult to pinpoint 
genes involved in tumor progression, metastasis or response to chemotherapy. However, it 
is well established that genetic alterations in the tumor suppressor genes Rb1 and TP53 are 









More than 70% of osteosarcomas have loss of heterozygosity (LOH) of the TP53 gene, 
20% present rearrangements, and 30% harbor mutations in TP53.41,44,45 The Rb1 gene was 
found to harbor LOH and mutations in more than 35% of osteosarcomas.44,46,47 The 
establishment of a murine model with mutant or deleted p53 that leads to development of 
osteosarcomas spontaneously in more than 50% of the mice, confirms the role of p53 in 
osteosarcoma development.19 Furthermore, MDM2 and COPS3, which are negative 
regulators of p53 that facilitate its proteasomal degradation, are amplified in 10% and 25% 
of osteosarcomas respectively.48,49 The Rb protein binds to the E2F transcription factor, and 
this complex represses the transcription of genes necessary for cell cycle transition from G1 
to S-phase.50 The Rb protein is regulated by CDKN2A/p16 and CDK4/CDK6. CDK4/CDK6 
phosphorylates Rb, thereby driving cell cycle progression, and CDKN2A/p16 inhibits the 
activation CDK4/CDK6.51 It has been shown that in osteosarcoma CDK4 is amplified in 10% of 
the tumors, and CDKN2A/p16 is deleted in tumors that lack Rb mutations.47,52–54  Deletion of 
CDKN2A/p16 is correlated with poor prognosis.1 Furthermore, a genome-wide expression 
study on a series of high-grade osteosarcomas compared to mesenchymal stem cells and 
osteoblasts, revealed significantly altered pathways in osteosarcoma such as upregulation of 
genes involved in mitosis and DNA replication.55 
c-Myc and c-Fos are two proto-oncogenes that are regulators of cell cycle 
progression by modulating the cyclin-Cdk complex activity.56,57 Expression of the c-Myc and 
c-Fos genes is increased in osteosarcoma.58 One of the frequent genomic gains found in 34% 
of the cases is chromosome arm 8q, which contains the c-Myc proto-oncogene,39,59 and its 
amplification is associated with poor overall survival and event-free survival.47 In a genetic 
mouse model, 100% of transgenic mice overexpressing c-Fos were found to develop 
osteosarcoma.58  
Figure 3. COBRA-FISH karyotype. Left)  Normal 
human cell. Right) Osteosarcoma cell. Courtesy of 
Dr. Karoly  Szuhai. 
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Receptor Tyrosine kinases (RTKs) are transmembrane receptors that are activated 
upon extracellular ligand binding such as growth factors, hormones and cytokines. They are 
mediators of the these environmental signals that lead to normal cellular processes like 
growth, proliferation, survival, differentiation and migration.60 If these receptors are 
mutated or abnormally activated, they can be effective oncoproteins driving 
tumorigenesis.61 The RTK family is composed of 58 members classified into 20 subfamilies62 
which include: epidermal growth factor receptors (EGFR), platelet-derived growth factor 
receptors (PDGFR), fibroblast growth factor receptors (FGFR), hepatocyte growth factor 
receptor (Met), insulin receptor (INSR), among others.63  
The EGFR family is composed of EGFR, ERBB2, ERBB3 and ERBB4.62 The EGFR gene 
was found to be amplified in 82% and expressed in 50% of osteosarcoma.64,65 However, 
inhibition of EGFR in vitro had no effect on cell viability in vitro, and in osteosarcoma 
patients high EGFR expression is correlated with good prognosis.66,67 There are contradicting 
results with respect to ERBB2 expression and its correlation with osteosarcoma prognosis, 
which could be due to study methodologies.68–70 Inhibition of ERBB3 expression in vitro and 
in vivo reduces cell growth and invasiveness of osteosarcoma cells71. Studies on ERBB4 in 
osteosarcoma are limited but it was found to be paired with ERBB2 for its activation.72 
PDGFR family is composed of CSF1R, KIT, FLT3, PDGFRα and PDGFRβ.62 The KIT gene 
was found to be amplified in 57% of osteosarcoma patients.73 PDGFRα/β were found to be 
expressed in osteosarcoma cell lines,74  however, in osteosarcoma patients expression of 
PDGFRα is not correlated with overall survival.75 No information is available on FLT3 and 
CSF1R in osteosarcoma.  
The FGFR family includes FGFR1/2/3/4.62 FGFR1 gene has been reported to be 
amplified in 17% of the osteosarcoma cases, and it was significantly correlated with poor 
response to chemotherapy.76 No studies have reported on the relation between FGFR2/3/4 
expression and osteosarcoma. 
Met is part of the Met family together with MST1R. Met is highly expressed in 
osteosarcoma, and it has been implicated in osteosarcomagenesis by inhibiting the 
differentiation of the osteo-progenitor cell population.77,78 Additionally, Met expression was 
associated with ostesarcoma progression and aggressiveness.79  
The INSR family groups the insulin receptor (IR) and the insulin-like growth factor 1 
receptor (IGF-1R). IGF-1R is known to be expressed in osteosarcoma and its downstream 
signaling pathway was found to be altered in osteosarcoma.80,81 However, IGF-1R expression 
is not proven to be a predictive marker for response to therapy with IGF-1R inhibitors.82  
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All these RTKs are activated by many different ligands, and to exert their effect they 
must activate downstream signaling pathways converting ligand binding into gene 
expression alterations. The pathway from cell surface to nucleus is mainly governed by: 1) 
the Ras/Raf/MEK/ERK cascade, 2) the PI3K/AKT pathway and 3) the Jak/STAT pathway.83  
The Ras/Raf/MEK/ERK cascade is known to be involved in cell proliferation, 
apoptosis, differentiation and development. Activated cell surface receptors lead to ERK 
activation, which activates transcription factors such as c-Myc, c-Fos, Ets, and Elk-1.84 This 
pathway is often deregulated in tumors caused by mutations or overexpression of upstream 
signaling components. B-Raf and Ras are frequently mutated in melanoma, colorectal 
cancer, ovarian cancer, lung cancer and pancreatic cancer among others.85,86 In 
osteosarcoma, the ERK pathway was reported to be active in 67% of the cases analyzed, and 
mutations in B-RAF were only found in 13% of the cohort.87 The PI3K pathway regulates 
processes such as proliferation, metabolism, apoptosis and cytoskeletal rearrangements.88 In 
osteosarcoma, genetic screens have identified this pathway to be upregulated.89–91 Recently, 
AKT2 was found to be overexpressed in osteosarcoma samples compared to normal tissue, 
and there was a positive correlation with shorter overall survival time.92 Furthermore, it has 
been reported that STAT3 is overexpressed and constitutively active in osteosarcoma, and 
contributes to tumor progression.93,94 Upstream of these three pathways is Src, a non-
receptor tyrosine kinase that belongs to a family of 11 members.95 It was shown that in 
osteosarcoma, Src expression and activity correlates with clinical stage and survival time.96  
Finally, another important pathway involved in osteosarcoma development is Wnt/β-
catenin. Active Wnt/β-catenin signaling stimulates osteogenic differentiation. This pathway 
was found to be inactive in osteosarcoma, thus facilitating dedifferentiation.97  
 
5. Metastatic behavior 
Osteosarcoma is a highly metastatic cancer. Approximately 20% of the patients present with 
pulmonary metastasis at the moment of diagnosis and when patients present with 
recurrence  around 90% of the cases is in the lungs.98 Ras/Raf/MEK/ERK activation 
downstream from IGF-1R has been shown to drive lung metastasis in an orthotopic mouse 
model.99 The PI3K/AKT pathway is also involved in osteosarcoma metastasis. Several studies 
showed that this pathway is active in cell lines capable of forming metastatic lesions in 
mice100 and that AKT activity is upregulated in anoikis-resistant cells.101  As mentioned 
before, Src kinase activity can stimulate these pathways. Src regulates a variety of cellular 
processes such as cell morphology, migration, adhesion, survival and proliferation.95 In cell-
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matrix adhesions where integrin receptors connect the intracellular cytoskeleton to the 
extracellular matrix; Src forms a complex with focal adhesion kinase (Fak). Src 
phosphorylates Fak at multiple positions thereby creating a cell adhesion signaling platform 
that regulates cell-matrix adhesion dynamics and downstream signaling.102 Fak is 
overexpressed in osteosarcoma, and it was shown to be involved in metastasis.103 Another 
cytoskeleton-associated protein that influences the metastatic behavior of osteosarcoma is 
ezrin. Ezrin links the cytoskeleton to the plasma membrane allowing the cell to interact with 
the environment. In osteosarcoma, ezrin is necessary for initial survival once the cells 
metastasize, and this effect is dependent on ERK activity. Moreover, high expression of ezrin 
is correlated with poor survival.104 Lastly, increased expression of vascular endothelial 
growth factor (VEGF), a factor that binds VEGF-R on endothelial cells and stimulates 
angiogenesis, has been reported as a prognostic marker in osteosarcoma105. 
 
6. Treatment options 
Historically, osteosarcoma was treated with amputation of the limb, and the maximum 5-
year survival rate was 20%. However, the majority of the patients died 2 years after 
diagnosis because of metastasis.106 As surgical techniques advanced, resection of the tumor 
was possible with limb-salvage techniques, and it was proven to be as safe as amputation.107 
After the introduction of chemotherapy the disease survival rate increased to >50% with 
patients surviving more than 5 years.108,109 Today, the treatment consists of preoperative 
chemotherapy followed by resection of the tumor. The most effective systemic 
chemotherapeutics are cisplatin,110 doxorubicin108 and methotrexate.111 Despite extensive 
studies aimed at finding optimal combined chemotherapeutic strategies, overall 5-year 
survival rates have not increased above 70%. Furthermore, around 35-45% of the patients 
have tumors that do not respond to chemotherapy.112–114 The mechanisms underlying such 
resistance are not well understood but may include p53 mutation as well as overexpression, 
rewiring of signaling pathways including PI3K/AKT and Ras/MAPK, and expression of ABC 
transporters.115,116  
There is a clear need for alternatives to conventional chemotherapy or to drugs that 
suppress the resistance to chemotherapy. Genome-wide RNA interference (RNAi) screening 
to identify new drug targets and screening of chemical compound libraries hold the promise 
of identifying new strategies for molecularly targeted therapy. RNAi screens in osteosarcoma 
have identified the mTOR pathway (downstream from PI3K/AKT), CDK11, WEE1 as candidate 
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drug targets among others.89,117–119 Other studies have reported that inhibition of Aurora 
A/B or polo-like kinase 1 sensitizes osteosarcoma cells to doxorubicin.120,121 
Some of the candidate therapeutic targets have entered clinical testing in 
osteosarcoma patients. Recently, a clinical trial studying the effect of Alisertib (Aurora A 
inhibitor) was completed (NCT01154816). There are several ongoing clinical trials that are 
studying the inhibition of VEGFR in solid tumors (NCT02389244, NCT02432274, 
NCT02357810, NCT02243605). Others are studying the possibility of inhibiting Src with 
saracatinib (NCT00752206) and dasatinib in combination with chemotherapy 
(NCT00788125). Besides inhibiting kinases, other trials are investigating the effect of 
targeting the immune system (NCT02470091, NCT00743496, NCT00134030). 
 
7. Aim and outline of this thesis 
The aim of the studies described in this thesis was to discover new therapeutic options for 
osteosarcoma patients. I focused on finding candidate targets and pharmaceutical inhibitors 
for killing human osteosarcoma cells or for sensitizing osteosarcoma cells to the 
chemotherapeutical, doxorubicin. Chapter 2 describes the role of Aven in cell cycle control in 
osteosarcoma cells. It shows that silencing Aven causes cell cycle arrest through 
downregulation of the checkpoint kinase, Chk1. It further explores the efficacy of small 
molecules targeting Chk1 in combination with doxorubicin. In chapter 3, the role of Bcl2 
family members in osteosarcoma cell survival is studied using an RNAi library targeting 
members of this family. Identification of Bcl-xL and validation of this hit using small 
molecules is described for a panel of human osteosarcoma cell lines. In Chapter 4 
identification of MEK inhibitors in a chemical kinase inhibitor library screen is described. 
Results are presented pointing to MEK inhibitors as a candidate therapeutic option for 
osteosarcomas showing high MEK activity. Chapter 5, focuses on elucidating the effect of 
three Src inhibitors on osteosarcoma viability and cell migration using 2D cultures and 
validation in 3D culture systems. Lastly, chapter 6 provides overall conclusions of the studies 
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Conventional high-grade osteosarcoma is the most common primary bone sarcoma with 
relatively high incidence in young people. Here, we found that expression of Aven is 
inversely correlated with metastasis-free survival in osteosarcoma patients and is increased 
in metastases compared to primary tumours. Aven is an adaptor protein that has been 
implicated in anti-apoptotic signaling and serves as an oncoprotein in acute lymphoblastic 
leukemia. In tumour cells, silencing Aven triggered a G2 cell cycle arrest. Chk1 protein levels 
were attenuated and ATR-Chk1 DNA damage response signaling in response to 
chemotherapy was abolished in Aven-depleted osteosarcoma cells while ATM, Chk2, and 
p53 activation remained intact. Osteosarcoma is notoriously difficult to treat with standard 
chemotherapy, and we examined whether pharmacological inhibition of the Aven-controlled 
ATR-Chk1 response could sensitize osteosarcoma cells to genotoxic compounds. Indeed, 
pharmacological inhibitors targeting Chk1/Chk2 or those selective for Chk1 synergized with 
standard chemotherapy in 2D cultures. Likewise, in 3D extracellular matrix-embedded 
cultures Chk1 inhibition led to effective sensitization to chemotherapy. Together, these 
findings implicate Aven in ATR-Chk1 signaling and point towards Chk1 inhibition as a strategy 
























Osteosarcoma is the most common primary malignant bone tumor occurring predominantly 
in children and adolescents, and a second peak at middle age. It is thought to arise from 
mesenchymal stem cells that are capable of producing osteoid [1,2]. At the moment of 
diagnosis, 10-20% of the patients present with metastasis. About 30-40% of the patients 
with localized osteosarcoma will relapse mainly by presenting lung metastasis. Patients with 
recurrence have very poor prognosis with 23-33% 5-year overall survival [3].  
 
Aven is an adaptor protein that exerts anti-apoptotic activity by potentiating Bcl-xL 
and by interfering with the self-association of Apaf-1, thereby preventing the activation of 
caspase 9[4,5]. Aven has also been identified through bioinformatics analysis as a novel 
potential BH3-domain containing protein[6]. Besides being involved in apoptosis, Aven was 
reported to control the DNA damage response (DDR) by physically interacting with- and 
supporting the activity of “ataxia-telangiectasia mutated” (ATM)[7]. 
 
The DDR is evolutionary conserved and essential to ensure the faithful maintenance 
and replication of the genome. This elaborate integrated signaling cascade senses DNA 
damage and triggers repair, cell cycle arrest and, in case of severe damage, cell death. The 
serine/threonine protein kinases of the phosphatidylinositol 3-kinase-like family, ATM and 
“ATM and Rad3-related” (ATR) are crucial players in the DDR [8,9]. After DNA damage, ATM 
and ATR are activated and, in turn, they activate critical effectors, including components of 
the DNA damage repair machinery and the checkpoint kinases, Chk1 and Chk2 to arrest the 
cell cycle[10]. Combining cytotoxic chemotherapeutics with pharmacological Chk1/Chk2 
inhibitors can prevent damaged cancer cells from arresting, causing increased tumor cell 
killing and thus, improved therapeutic efficacy [11]. 
 
In the context of cancer, Aven has thus far been exclusively implicated in 
hematopoietic malignancies. Aven mRNA levels have been associated with disease relapse 
and poor prognosis of acute lymphoblastic leukemia and Aven has been shown to act as an 
oncoprotein that drives proliferation and survival of leukemic cells [12-14]. Here, we analyze 
Aven mRNA, protein expression, and function in osteosarcoma, the most common primary 
bone malignancy that is very difficult to treat. We show that Aven expression is increased in 
metastatic lesions and inversely correlated with metastasis-free survival in osteosarcoma 
patients. We show that Aven is in fact dispensable for ATM-Chk2 (and p53) activation. 
Instead, Aven is required for ATR-Chk1 signaling and Aven silencing leads to G2 cell cycle 
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arrest. Moreover, in the absence of Aven osteosarcoma cells fail to activate Chk1 (but not 
Chk2) in response to DNA damaging chemotherapeutics. Finally, we show that targeting the 
Aven-controlled ATR-Chk1 activity using clinically relevant pharmacological inhibitors 
sensitizes osteosarcoma to chemotherapy. 
 
MATERIALS AND METHODS 
 
Reagents and antibodies.  Doxorubicin was obtained from the Department of Clinical 
Pharmacology at LUMC, AZD7762 Chk1/Chk2 inhibitor. Ly2603618 and CHIR-124 selective 
Chk1 inhibitors were from SelleckChem (Huissen, Netherlands). Cisplatin and etoposide were 
from Sigma-Aldrich (Zwijndrecht, The Netherlands). Hoechst 33342 was purchased from 
Fischer Scientific (Bleiswijk, The Netherlands) and the pan-caspase inhibitor z-VAD-fmk was 
obtained from Bachem (Weil am Rhein, Germany). The Aven antibody (HPA020563) used for 
immunohistochemistry was from Sigma Aldrich (Zwijndrecht, The Netherlands) and the Aven 
antibody (2300S) used for Western blot was from Cell Signalling (Bioké, Leiden, The 
Netherlands). The antibody against phospho-ATR(Ser428) (2853) was from Cell Signaling 
(Bioké, Leiden, Netherlands). The antibody against tubulin (T-9026) was from Sigma-Aldrich 
(Zwijndrecht, Netherlands). Antibodies against phospho-H3(ser10) (9701), phospho-
CHK2(Thr68) (2661P), phospho-H2Ax(Ser139) (9718), phospho-ATM(Ser1981) (5883), and 
CHK1 (2345) were from Cell Signaling (Bioké, Leiden, Netherlands). The antibody against 
phospho-CHK1(Ser317) (A300-163A) was from Bethyl Laboratories (Uithoorn, The 
Netherlands). 
 
Microarray data analysis. Gene expression profiles were obtained from a previously 
published microarray data set [15]. Kaplan Meier curves were created from the entry “Mixed 
Osteosarcoma-Kuijer-127-vst-ilmnhwg6v2” in the web application R2 (http://r2.amc.nl). 
 
Immunohistochemistry on tissue microarrays. Tissue microarrays used in this study were 
previously constructed and published [16]. All specimens in this study were handled 
according to the ethical guidelines described in ‘Code for Proper Secondary Use of Human 
Tissue in The Netherlands’ of the Dutch Federation of Medical Scientific Societies. The slide 
was deparaffinized, rehydrated and blocked of endogenouse peroxidase. Subsequently, 
antigen retrieval was performed with citrate pH 6.0. Incubation with antibody was overnight 
at 4°C at a 1:1000 dilution. As a second step we used Immunologic Poly-HRP-GAM/R/R IgG 
(DVPO110HRP) and Dako liquid DAB+ Substrate Chromogen System (K3468), after which it 
was counterstained with hematoxiline. Testis tissue was used as control. Slides were scored 
independently by two observers (JVMGB and ZB). Staining intensity (0 = absent, 1 = weak, 2 
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= moderate, 3 = strong) and extent of the staining (0 = 0%, 1 = 1-24%, 2 = 25-49%, 3 = 50-
74% and 4 = 75-100%) were assessed. The two values were added to obtain the score sum. 
Cores where the tissue was lost were excluded from the analysis.  
 
Cell culture. Human osteosarcoma cell lines MOS, U2OS, 143B, ZK58 and KPD used were 
previously described [17,18]. Cells were grown in RPMI1640 medium supplemented with 
10% fetal bovine serum and 25 U/mL penicillin and 25 µg/mL of penicillin-streptomycin.  All 
cells were cultured in a humidified incubator at 37°C with 5% CO2.  
 
siRNA transfection. Transient knockdown of individual genes was achieved using siGenome 
SMARTpool siRNAs from Dharmacon, Thermofisher Scientific (Landsmeer, Netherlands). The 
end concentration of siRNA was 20nM and it was delivered to the cells by INTERFERin siRNA 
transfection reagent according to the manufacturer’s procedures (Polyplus transfection, 
Leusden, Netherlands). Medium was refreshed 24 hours post transfection and transfected 
cells were used in experiments 48 hours post transfection. The sequences of siRNA are 
GAUUAGGGAUGCAGUUAAA, GAACAGGGAAAUUAUUCUA, UAACUGGGAUCGAUAUCAA and 
GUUAUUGGUUCGAGCCCUU. 
 
Cell cycle analysis. Cell cycle analysis was performed using the Click-iT® Edu Flow Cytometry 
Assay Kit from Invitrogen (Oregon, USA). Cells were exposed to 10µM 5-ethynyl-2-
deoxyuridine (Edu) for 1 hour followed by fixation, permeabilization, and staining. RNAase 
was added to each sample to a final concentration of 20mg/mL. Edu was probed with Pacific 
Blue azide and DNA was stained with FxCycleTM Far Red Stain with a final concentration of 
200nM. 
 
Immunoblotting. Cells were lysed with SDS protein buffer (125mM Tris/HCl pH 6.8, 20% 
glycerol, 4% SDS and 0.2% bromophenol blue). Proteins were resolved by SDS-PAGE and 
transferred to polyvinylidine difluoride membrane. Membranes were blocked in 5% BSA-
TBST (TRIS-0.05% Tween20), followed by overnight incubation with primary antibodies and 
45 minutes incubation with HRP-conjugated secondary antibodies. Chemoluminescence was 
detected with a Typhoon 9400 imager (GE Healthcare). 
 
Cell number, cell viability, and real time growth assays. Control or siRNA-transfected cells 
were treated with compounds for the indicated time points in black 96-well µ-clear plates 
(Greiner). To determine cell numbers, cells were fixed in 4% paraformaldehyde for 15 
minutes and nuclei were stained with Hoechst 33342 for 15 minutes. Plates were imaged 
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using a BD Pathway 855 imager (Becton Dickinson). Images were processed using an Image-
Pro Analyzer 7.0 algorithm, yielding the number of nuclei in each well. For cell viability, cells 
were processed using the ATPlite 1Step kit (Perkin Elmer) according to the manufacturer’s 
instructions, followed by luminescence measurement on a plate reader. For real time cell 
growth analysis the RTCA xCELLigence system (Roche Applied Sciences, Almere, The 
Netherlands) was used. In this system cells are plated on a surface covered with electrodes 
that measures cell impedance displayed as cell index. Cell index is a quantitative measure of 
the number of cells present in the well. For the assay, the cells were seeded in an E-View 96 
well plate and loaded into the RTCA station immediately. The cells were exposed to 
compounds 16 hours later, and further monitored for 72 hours. Measurements were taken 
every 15 minutes. 
 
Real time qPCR. RNA was isolated from control or siRNA-transfected cells using RNeasy 
(Qiagen). cDNA was generated from 500 ng total RNA using RNeasy Plus Kit from Qiagen. 
Real time qPCR was performed in triplicate using the SYBRGreen PCRMasterMix (Applied 
Biosystems) on a 7900HT fast real-time PCRsystem (Applied Biosystems). Primer sequence 
for CHK1 employed were: forward TGGTATTGGAATAACTCACAGGGA and reverse 
TGTTCAACAAACGCTCACGA. Data were collected and analyzed using SDS2.3 software 
(Applied Biosystems). Relative mRNA levels after correction for GAPDH control mRNA were 
expressed using 2^(-∆∆Ct) method. 
 
3D culture assay. U2OS and MOS cells were cultured in 384-well plates (Greiner μclear) in a 
hydrogel containing Matrigel (Beckton Dickinson) and collagen I, supporting invasive growth 
of both cell lines. Cells in culture were trypsinized and directly added to the cooled gel 
solution. Using a robotic liquid handler (CyBio Selma 96/60), 14.5μL of gel-cell suspension 
was transferred to each well of a 384-well plate (2000 cells/well). After polymerization for 30 
minutes at 37°C in an atmosphere of 5% CO2, growth medium was added on top of the gel. 
After three days, when the cells had formed a network structure, compounds were diluted 
and added in quadruplicate wells for a period of 72 hours. For measuring cell viability in 3D, 
a solution of 7g/L WST-1 (Serva Electrophoresis) and 8mg/L phenazinium methylsulfate 
(PMS; Sigma Aldrich) in 1x PBS were mixed in a 1:1 ratio and 5μL was added to each well. 
Plates were placed at 37°C for 5 hours, after which the absorbance at 450nm was measured 
using a FluoStar plate reader. Percentage viability was thereafter calculated by robust 
normalization (median) of the plates between positive control (no cells; 0% viability) and 




For imaging, cells were fixed using 3.7% Formaldehyde (Sigma-Aldrich), permeabilized with 
0.1% Triton-X100 and stained for F-actin using 50nM Rhodamine-Phalloidin (Sigma Aldrich) 
for 12 hours at 4˚C . Subsequently, the plates were washed in PBS for at least 24 hours at 
4˚C. The plates were then imaged on a BD Pathway 855 inverted fluorescence microscope 
(BD Biosciences) using a 4x lens to capture Rhodamine-Phalloidin staining at focal planes 
spaced 50µm throughout the gel, capturing approximately 70% of a well. Subsequently, 
maximum intensity projections of the in-focus information of the Z-stacks was made using 
OcellO (OcellO B.V., Leiden, The Netherlands) image analysis tools. 
 
Synergy assessment. To assess synergy, we used the Bliss independence model, which 
defines that the effect of a drug at certain concentration is independent of the presence of 
the other drug.[19] This model predicts the combined response C for two single compounds 
with effects A and B: C = A + B – A•B [20]. 
 
Statistical analysis. Dose response curve fitting and all statistical analyses were performed 
with GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA). The unpaired two-tailed t-test 
was used to compare between groups. Significant difference between groups in the 3D assay 




Aven expression in human osteosarcoma samples 
We used a previously published microarray data set[21] with available follow-up data to 
search for mRNAs whose expression correlated with metastasis-free survival in 
osteosarcoma patients. We used 53 osteosarcoma samples for which associated survival 
data were available. These were arranged by Aven mRNA expression level, and the median 
was used to divide the set in cases with high and low expression. The cutoff set by R2 was 
218.6 with a raw p-value of 0.03. Using this approach, high expression of Aven significantly 
correlated with a lower metastasis-free survival probability (Fig 1A). Next, we assessed Aven 
protein expression by immunohistochemistry in 31 human primary osteosarcomas and 8 
osteosarcoma lung metastases by immunohistochemistry. Aven protein was detected in 
most samples and expression was significantly higher in metastases as compared to primary 








Figure 1. Aven expression in osteosarcoma biopsies. A) Kaplan Meier curve showing relation 
between Aven mRNA expression and metastasis-free survival. Expression of Aven mRNA was 
analyzed in 53 samples with survival data, and arranged by expression. The cohort was divided into 
high and low expression at the median. The curve was made using http://r2.amc.nl. p values were 
determined by Bonferroni testing. B) Sum score of Aven expression in all tumors included in the 
tissue microarrays. Average is shown in red; p values were determined by two-tailed t test. C) 










Aven silencing attenuates growth of human osteosarcoma cells  
To determine Aven’s role in osteosarcoma cell viability and growth we silenced the AVEN 
gene in two human osteosarcoma cell lines: MOS and U2OS. We used a Smartpool of 4 
siRNAs that led to a near complete loss of Aven protein at 48 hours after transfection in both 
cell lines (Fig 2A). In U2OS cells, transfection with this Smartpool or with any of the four 
individual siRNAs led to a 60-80% reduction in cell numbers as compared to control, GAPDH-
silenced cells (Fig 2B). Likewise, MOS cells transfected with siAven showed a 60% reduction 
in cell numbers compared to controls (Fig 2C). Aven has been reported to suppress apoptosis 
in other cell types [4,5,22]. To test if increased apoptosis was responsible for the reduced 
cell numbers, MOS cells transfected with siAven were treated with the pan-caspase 
inhibitor, z-VAD-fmk. This led to a slight increase in cell numbers but did not restore growth 
to that of cells transfected with control siRNAs (Fig 2C). The same results were obtained with 
U2OS: treatment with z-VAD-fmk did not restore growth of Aven-silenced cells (Fig 2D). 
 
Aven silencing in human osteosarcoma cells triggers G2 cell cycle arrest 
We next made use of the RTCA XCelligence system for real time analysis of the effect of 
Aven silencing on human osteosarcoma cell populations. MOS cells that were MOCK (no 
siRNA) or siGAPDH transfected, expanded over approximately 24 hours followed by a 
plateau phase after reaching confluence, whereas siAven-transfected MOS cells stopped 
expanding at ~18 hours post transfection (Fig 3A). Similarly, a prolonged gradual increase in 
cell index that was observed for U2OS cells was terminated after 18 hours in response to 
Aven silencing. This indicated that Aven might be required for effective proliferation of 
osteosarcoma cells. Indeed, phosphorylation of Histone H3 Ser10 that is associated with 
mitosis was attenuated in siAven-transfected MOS and U2OS cells, indicating that Aven 
supported cell cycle progression (Fig 3B). Furthermore, FACS analysis of MOS and U2OS cells 
pulsed with Edu for 1 hour showed a reduction of cells in S-phase (t-test, p<0.05) and a 





Figure 2. Effect of Aven silencing. A) Western blot analysis of Aven protein abundance and tubulin 
loading control in MOS and U2OS cells transfected for 48 hours with indicated siRNA Smartpools. B) 
Relative cell numbers based on Hoechst staining, 72 hours post transfection in U2OS cells transfected 
with GAPDH or Aven siRNA Smartpools or with Aven single siRNAs. Mean +/- SD for experiment 
performed in quadruplicate is shown. C,D) Relative cell numbers based on Hoechst staining for MOS 
and U2OS cell lines, 72 hours post-transfection with indicated siRNA Smartpools. Cells were treated 
with or without z-VAD-fmk during the last 24 hours (starting at 48 hours post transfection. Mean +/- 







Figure 3. Aven silencing leads to cell cycle arrest. A) Subconfluent cultures of MOS and U2OS cells 
untransfected (MOCK, green) or transfected with control siGAPDH (black) or siAVEN (red) were 
monitored for 60 hours with RTCA Xcelligence System. Medium was refreshed at 18 hours post-
transfection. Representative experiment of two biological replicates, performed in quadruplicate is 
shown. B) Western blot analysis of total and phospho(Ser10) histone H3 and tubulin loading control 
for MOS and U2OS cells transfected with siAVEN or siGAPDH for 48 hours. C) Flow cytometry analysis 
of DNA content (x-axis) and Edu incorporation (Y-axis) in MOS and U2OS cells transfected with 
siAVEN or control siGAPDH pulsed for 1 hour with 10μM Edu after 48 hours. Representative 
experiment from three biological replicates is shown. D) Quantification of data from C. Mean and 
SEM of three independent experiments is shown. 
 
 
Aven silencing attenuates ATR-Chk1 DDR signaling in human osteosarcoma cells 
The role of Aven in DDR signaling has been attributed to its interaction with ATM [7]. ATM 
senses double-strand breaks, becomes activated, and subsequently phosphorylates 
downstream substrates, including Chk2 and p53 [23]. We analyzed ATM activation in U2OS 
and MOS cells treated for 4 hours with 1 µM doxorubicin. Surprisingly, silencing Aven led to 
enhanced doxorubicin-induced ATM activation as measured by ATM auto-phosphorylation 
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at Ser1981 in MOS and U2OS cells (Fig 4A). Chk2 levels increased in response to Aven 
depletion in these cells (Fig 4B,C). Chk2 phosphorylation at the Thr68 ATM target site was 
not evident in U2OS cells and in MOS cells doxorubicin triggered ATM Thr68 phosphorylation 
irrespective of the absence or presence of Aven siRNAs (Fig 4B,C). Likewise, in MOS as well 
as U2OS cells doxorubicin treatment caused a strong phosphorylation of p53 at the 
ATM/ATR target site, Ser15 and this response was not affected by Aven silencing (Fig 4B,C). 
 
ATR is activated in response to persistent single-stranded DNA, which is exposed at 
stalled replication forks and as an intermediate in several DNA damage repair pathways [23]. 
Doxorubicin treatment caused increased ATR phosphorylation at Ser428 in MOS and U2OS 
cells, a response that was abolished by Aven silencing (Fig 4A). Moreover, phosphorylation 
of Chk1 at the ATR target site Ser317 after exposure to doxorubicin was also prevented in 
Aven-depleted MOS and U2OS cells (Fig 4B,C). This was accompanied by a loss of Chk1 
protein accumulation in response to doxorubicin. The role of Aven in the accumulation and 
phosphorylation of Chk1 was not restricted to doxorubicin but Aven was similarly required 
for this response in the context of treatment with 5µM cisplatin or 5µM etoposide (Fig 4D). 
qPCR analysis showed that changes in Chk1 protein abundance were not due to changes in 
mRNA (Fig S1). Notably, this also excluded a reduction of Chk1 levels through off-target Aven 
siRNA effects.  
 
Together, these findings indicated that Aven supports ATR-Chk1, but not ATM-Chk2 
DDR signaling in osteosarcoma cells. In contrast to ATM-Chk2 signaling, which is particularly 
important for the response to double strand breaks, ATR-Chk1 signaling is also required for 
mitotic progression in unperturbed cells [24]. We examined whether the slightly reduced 
levels of Chk1 (Fig 4B-D) could underlie the cell cycle arrest in Aven-depleted cells. In support 
of this, silencing Chk1, but not Chk2, impaired MOS cell growth to a similar extent as 
observed with Aven siRNAs (Fig 2C; S2). 
 
Pharmacological inhibition of Chk1 sensitizes osteosarcoma cells to doxorubicin   
Our findings thus far, suggested that Aven-controlled Chk1 signaling might represent an 
attractive target to sensitize osteosarcoma cells to chemotherapy. Aven inhibitors are not 
available, but novel Chk1/2 inhibitors that have already been tested in clinical trials are. 
Therefore, MOS and U2OS cells were treated with a concentration range of the Chk1/2 
inhibitor, AZD7762, in combination with a concentration range of doxorubicin. Ranges were 





Figure 4. Aven silencing causes shift from ATR-Chk1 to ATM-Chk2 DDR signaling. A) Western blot 
analysis of total and phospho(Ser1981) ATM, total and phospho(Ser428) ATR, and tubulin loading 
control for MOS (top) and U2OS cells (bottom) transfected 48 hours with siGAPDH or siAVEN and 
subsequently treated with 1μM doxorubicin for 4 hours. One representative experiment of 3 is 
shown.  B,C) Western blot analysis of total and phospho(Thr68) Chk2, total and phospho(Ser317) 
CHK1, total and phospho(ser15) p53, and tubulin loading control for MOS (B) and U2OS cells (C) 
transfected 48 hours with siGAPDH or siAVEN and subsequently treated with 1μM doxorubicin for 4 
hours. One representative experiment of 3 is shown. D) Western blot analysis of total and 
phospho(Thr68) Chk2, total and phospho(Ser317) CHK1, and tubulin loading control for MOS cells 
transfected 48 hours with siGAPDH or siAVEN and subsequently treated with PBS, 5μM cisplatin (CP), 
or 5μM etoposide for 4 hours.  
 
 
of MOS with 25-100 nM AZD7762 by itself did not affect cell viability but it led to a strong 
sensitization to low (50-100 nM) concentrations of doxorubicin (Fig 5A). Calculation of the 
deviation from additivity as predicted by Bliss independence [19], indicated synergy between 
AZD7762 and doxorubicin (Fig 5B). The same synergistic relationship between these two 
compounds was observed for U2OS cells (Fig 5C,D). We further explored the AZD7762-
doxorubicin combination using three other human osteosarcoma cell lines, ZK58, KPD, and 
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143B. Again, 50 nM AZD7762 slightly increased the effect of doxorubicin on ZK58 and 
strongly sensitized KPD and 143B cells to doxorubicin treatment (Fig 5E). 
We also examined the interaction of two clinically relevant selective CHK1 inhibitors, 
CHIR-124 and LY2603618 with doxorubicin in osteosarcoma cells. CHIR-124 by itself already 
affected viability at concentrations above 25 nM, especially in U2OS cells (Fig 5F,G). At 25 
nM, CHIR-124 sensitized MOS and to a lesser extent, U2OS to doxorubicin (Fig 5F,G; S5). Up 
to 0.25 μM LY2603618 by itself did not affect either cell line but at this concentration 
LY2603618 strongly augmented the effect of low concentrations of doxorubicin in U2OS and, 
especially in MOS cells (Fig 5H,I; S5). 
 
2D and 3D osteosarcoma cultures are chemosensitized by Chk1 inhibition 
We confirmed chemosensitization by Chk inhibition by monitoring the cells over a period of 
96 hours using the xCELLigence system. Growth of U2OS cells exposed to 0.1 μM doxorubicin 
was similar to growth under control conditions whereas treatment with 0.5 μM doxorubicin 
caused a loss of cells (Fig 6A). Again, exposure to 50 nM AZD7762 had no effect by itself but 
effectively sensitized U2OS cells to 0.1 μM doxorubicin (Fig 6A). 
We further validated the possibility of chemosensitization by Chk1 inhibition using 3D 
osteosarcoma cell cultures. MOS and U2OS cells were suspended in a mixture of collagen 
and matrigel and allowed to grow for three days. Subsequently, cultures were exposed to a 
dose rage of doxorubicin in the absence or presence of 50 nM AZD7762, 25nM CHIR-124, or 
0,125μM LY2603618 for 72 hours and viability was determined using a biochemical assay. 
Similar to the results in 2D cultures, MOS and to a lesser extent U2OS were sensitized in 3D 
to low doses of doxorubicin when Chk1/2 was inhibited using AZD7762 (Fig 6B,C).  
 
Likewise, 3D cultures of U2OS and especially MOS were effectively sensitized to 
doxorubicin by the two selective Chk1 inhibitors CHIR-124 and LY2603618 (Fig 6B,C). 
Moreover, image-based analysis at the same time as biochemical viability assessment 
showed that combined exposure to 50nM AZD7762 and 0.05μM doxorubicin caused 
disruption of the multicellular network, which was not seen when either of these drugs was 







Figure 5. Treatment with Chk1 inhibitor sensitizes osteosarcoma cells to doxorubicin.   
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A,C) Combined effect of doxorubicin and AZD7762 dose ranges in MOS (A) and U2OS cell (C). Mean 
of triplicates is shown. Each graph shows one representative of three independent experiments. B,D) 
Needle graphs showing deviation from Bliss-predicted additivity based on data shown in A,C. Mean 
of triplicates is shown. Each graph shows one representative of three independent experiments. E) 
Doxorubicin dose response curves for three human osteosarcoma cell lines as indicated in absence or 
presence of 50nM of AZD7762. Cells were exposed for 72 hours. Each graph represents mean ± SEM. 
F,G) Combined effect of doxorubicin and CHIR-124 dose ranges in MOS (F) and U2OS (G) cells. Mean 
of triplicates is shown. Each graph shows one representative of three independent experiments. H,I) 
Combined effect of doxorubicin and LY2603618 dose ranges in MOS (H) and U2OS (I) cells. Mean of 






Our data point to a role for Aven in growth and therapy resistance of osteosarcomas. High 
expression of Aven mRNA correlates with low metastasis-free survival in conventional 
osteosarcoma patients and Aven protein expression is high in metastasis as compared to 
primary biopsies of osteosarcoma. Aven has been shown to suppress apoptosis through its 
ability to enhance the anti-apoptotic effect of BCL-xl and to interfere with Apaf-1-mediated 
apoptosome formation in leukemic and breast cancer cells [4,5,14].  In human osteosarcoma 
cells we find that depletion of Aven does not trigger cell death through apoptosis. Rather, it 
leads to a G2 cell cycle arrest and ultimately to loss of viability by a mechanism that is not 
caspase-dependent. Instead, our findings indicate that this is due to impaired checkpoint 
kinase signaling. 
 
Checkpoint kinases Chk1 and Chk2 coordinate progression through the cell cycle[23,25] and 
Chk1 is expressed in S through M phase of the cell cycle [26]. Aven-depleted osteosarcoma 
cells have reduced phospho-Chk1(Ser317) and total Chk1 protein levels. Thus, Aven supports 
Chk1 protein synthesis or stability. As Ser317-phosphorylated Chk1 is required for DNA 
replication and mitotic progression [24], the important role we identify for Aven in 







Figure 6. Osteosarcoma cells are sensitized to doxorubicin by Chk1 inhibition in a 2D and 3D 
environment. A) Subconfluent U2OS cultures were monitored for 90 hours with RTCA Xcelligence 
System. Cells were exposed 16 hours after seeding to vehicle (black line), 50nM AZD7762 (green 
line), 0.1μM doxorubicin (blue line), 0.5 μM doxorubicin (orange line), or 0.1μM doxorubicin in 
combination with 50nM AZD7762 (red line). One experiment of two independent experiments done 
in quadruplicate is shown. B,C) Cell viability measured by WST assay in 3D extracellular matrix-
embedded MOS (B) and U2OS cultures (C) grown for 3 days and subsequently exposed to indicated 
compound concentrations for 72 hours. Mean ± SD of triplicates (MOS cells) or quadruplicates (U2OS 
cells) are shown. D) Representative images of 3D cultures of MOS cells exposed to DMSO, 50nM 
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AZD7762, 0.05μM doxorubicin, or the combination of the two drugs. Images are compressed z-stacks 
of actin cytoskeletal staining (Rhodamine-Phalloidin). 
 
 
The anti-apoptotic role of Aven is especially prominent in the response to genotoxic 
therapy. Overexpression of Aven in leukemic and breast cancer cells promotes resistance to 
γ irradiation and DNA damaging agents such as UV, SN-38 and cisplatin [4,5]. In addition to 
its role in BCL-xl function and interference with Apaf-1-mediated apoptosome formation as 
discussed above, this may be related to its role in DDR signaling. Aven has been shown to 
support ATM activation in cycling Xenopus eggs and in HeLa cells treated with 
neocarzinostatin [7]. Remarkably, our findings demonstrate that ATM activation in response 
to doxorubicin is fully intact or even potentiated in Aven-silenced osteosarcoma cells. 
Instead, we show that ATR activation in response to genotoxic stress is abrogated in the 
absence of Aven. 
 
ATM is mainly activated by double strand breaks, subsequently activating Chk2 to 
induce cell cycle arrest or apoptosis when the damage is extensive [9]. ATR is an essential 
regulator of genome integrity, responding to various types of DNA damage and it activates 
Chk1 [8]. However, crosstalk between ATM and ATR occurs and Chk1 activation by ATR in 
the context of double strand breaks is dependent on ATM [27,28]. Our data implicate Aven 
in ATR-Chk1 activation under conditions of genotoxic stress whereas baseline ATR Ser428 
phosphorylation appears unaffected by Aven silencing. This suggests that Aven may facilitate 
the interaction between ATM and ATR, driving ATR signaling in response to double strand 
breaks. 
 
We show that in osteosarcoma cells, the absence of Aven shifts the DDR from ATR-
Chk1 to ATM-Chk2 signaling. This does not affect the activation of p53 in response to 
genotoxic stress. In U2OS cells expressing wild type p53 as well as in MOS cells expressing a 
mutant p53, silencing Aven does not affect phosphorylation of p53 at the ATM/ATR target 
site Ser15 in response to doxorubicin. Under these conditions, ATM, either directly or 
through Chk2 likely phosphorylates p53 at Ser15 in response to DNA damage [29]. 
 
As a potential scaffold protein without enzymatic activity, Aven is unlikely to 
represent a candidate drug target. However, our data show that Aven-controlled Chk1 
signaling may well be an interesting drug target in osteosarcoma. Depletion of Chk1, but not 
Chk2, to some extent phenocopies the effect of Aven silencing and pharmacological 
inhibition of Chk1 at higher compound concentrations has the same effect. The use of Chk1 
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inhibitors for osteosarcoma appears most promising in a combination strategy. Chk1 
inhibition is already used as a therapeutic approach to potentiate the efficacy of genotoxic 
chemotherapeutics in other cancer types [30]. 
 
The Chk1/Chk2 inhibitor, AZD7762, is known to potentiate the effect of cisplatin in 
ovarian clear cell carcinoma [31] as well as in multiple myeloma cells [32]. It was also 
reported to sensitize pancreatic tumor cells to radiation and to interfere with DNA repair in 
these cells [33]. However, recently it was reported that this drug would not be continued in 
clinical trials due to cardiac toxicity [34]. We have tested two selective Chk1 inhibitors, CHIR-
124 and LY2603618. The latter drug was tested in a phase I dose-escalation study, and 
acceptable safety and pharmacokinetic profiles were reported [35,36].  Here, in 2D as well as 
3D cultures of human osteosarcoma cells, low concentrations of Chk1 inhibitors cause 
effective sensitization to low concentrations of doxorubicin. Doxorubicin is routinely used in 
the treatment of osteosarcoma patients but resistance is a major obstacle [37]. Our findings 
indicate that abrogation of Chk1 signaling using clinically relevant drugs may be combined 
with chemotherapy to more effectively treat osteosarcoma. 
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Figure S1) qPCR analysis showing Chk1 mRNA levels in U2OS cells transfected 48 hours with the 
indicated siRNAs. Mean +/- SEM of 3 independent experiments done in triplicate is shown. 
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Figure S2) MOS cells were transfected with siGAPDH, siChk1, siChk2 for 72 hours and cell numbers 
were determined by HOECHST staining and nuclei counting. 
Figure S3) Dose response curve of Doxorubicin in MOS and U2OS cells; 72 hours exposure. Mean +/- 
S.D of one experiment done in triplicate. 
Figure S4) Dose response curve of AZD7762 in MOS (black line) and U2OS cells (blue line); 72 hours 
exposure. Mean +/- SEM of 3 independent experiments done in triplicate is shown.  
Figure S5) Needle graphs showing deviation from Bliss-predicted additivity in MOS (top) and U2OS 
cells (bottom) exposed to doxorubicin and CHIR-124 dose ranges (left) or doxorubicin and LY2603618 
dose ranges (right). Each graph shows one representative of three independent experiments 
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High-grade conventional osteosarcoma is the most common primary bone sarcoma. 
Prognosis for osteosarcoma patients is poor and resistance to chemotherapy is common. We 
performed an siRNA screen targeting members of the Bcl-2 family in human osteosarcoma 
cell lines to identify critical regulators of osteosarcoma cell survival. Silencing the anti-
apoptotic family member Bcl-xL but also the pro-apoptotic member Bak using a SMARTpool 
of siRNAs as well as 4/4 individual siRNAs caused loss of viability. Loss of Bak impaired cell 
cycle progression and triggered autophagy. Instead, silencing Bcl-xL induced apoptotic cell 
death. Bcl-xL was expressed in clinical osteosarcoma samples but mRNA or protein levels did 
not significantly correlate with therapy response or survival. Nevertheless, pharmacological 
inhibition of a range of Bcl-2 family members showed that inhibitors targeting Bcl-xL 
synergistically enhanced the response to the chemotherapeutic agent, doxorubicin. Indeed, 
in osteosarcoma cells strongly expressing Bcl-xL, the Bcl-xL-selective BH3 mimetic, WEHI-539 
potently enhanced apoptosis in the presence of low doses of doxorubicin. Our results 























Osteosarcoma is the most common primary malignant bone tumor occurring predominantly 
in the second decade of life, and a second peak at middle age. It is thought to arise from 
mesenchymal stem cells that can produce osteoid [1-3]. About 30-40% of the patients with 
localized osteosarcoma will relapse mainly by presenting with lung metastasis. 
Approximately 10-20% of the patients present with metastasis at the moment of diagnosis. 
Since the introduction of chemotherapy patients with local disease have 50-60% long-term 
survival rate. There has been no significant further improvement over the past three 
decades [4]. Following disease relapse, prognosis is very poor with 23-33% 5-year overall 
survival despite repeated metastasectomies when feasible [5]. 
 
Apoptosis is a form of programmed cell death, which requires caspase-mediated 
proteolysis, and is governed by the Bcl-2 family. It is essential for development and tissue 
homeostasis, and can mediate cell death upon exposure to pathogens, cytotoxic agents, or 
oncogenic stress[6]. The Bcl-2 family includes BH3-only proteins (Bim, Puma, Bad, Noxa, Bik, 
Hrk, Bmf and tBid), pro-survival proteins (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, Bfl-1, and Bcl-B) and 
pro-apoptosis proteins (Bax, Bak and Bok). Bok is primarily localized to ER and Golgi 
membranes where it was found to be important for a proper ER stress response. Its 
overexpression induces apoptosis in a manner that is dependent on Bax and Bak[7]. Bak is 
localized to mitochondria and Bax resides in the cytosol. Once Bak and Bax are activated, 
they undergo conformational changes and Bax localizes to the mitochondria. In the 
mitochondria, Bak and Bax form hetero and oligomers which lead to mitochondrial outer 
membrane permeabilization and cytochrome-c release, which is necessary for caspase 
activation[8]. Under normal conditions, the pro-survival Bcl-2 members form heterodimers 
with Bax or Bak inhibiting their activation. However, under cytotoxic stress the activated 
BH3-only proteins displace these proteins allowing Bax and Bak to cause cytochrome-c 
release from the mitochondria, caspase cascade activation, and ultimately cell death [8,9]. 
 
Impaired apoptosis is one of the hallmarks of cancer [10].  It allows cancer cells to 
tolerate oncogenic stress and survive in hostile environments such as hypoxic conditions. 
Furthermore, defects in apoptosis in cancer cells can hamper the response to chemotherapy 
[11]. In this study we used RNA interference and pharmacological inhibition to identify 





MATERIALS AND METHODS 
 
Reagents and antibodies. Doxorubicin was obtained from the Pharmacy at the Leiden 
University Academic Hospital, ABT-737, UMI-77 and HA14-1 were from SelleckChem 
(Huissen, Netherlands). WEHI-539 was from ApexBio (Texas, U.S.A.). The pan-caspase 
inhibitor z-VAD-fmk was obtained from Bachem (Weil am Rhein, Germany). The Bcl-xL 
antibody (clone 54H6) used for immunohistochemistry ,the Bcl-xL antibody (2762s) used for 
Western blot and Bak antibody were from Cell Signaling (Bioké, Leiden, The Netherlands). 
LC3 antibody was from Novus Biologics (Cambridge, England) and Ki67 was from Abcam 
(Cambridge, England). Chloroquine was bought from Sigma Aldrich (Zwijndrecht, The 
Netherlands). Hoechst 33342 was purchased from Fischer Scientific (Bleiswijk, The 
Netherlands). 
 
Immunohistochemistry on tissue microarrays. Two tissue microarrays used in this study 
were previously constructed with one was previously published[3]. The second tissue 
microarray consisted of 73 FFPE biopsies, resections and metastases mainly from high grade 
conventional osteosarcomas. All specimens in this study were handled according to the 
ethical guidelines described in ‘Code for Proper Secondary Use of Human Tissue in The 
Netherlands’ of the Dutch Federation of Medical Scientific Societies. The slide was 
deparaffinized, rehydrated and blocked of endogenouse peroxidase. Subsequently, antigen 
retrieval was performed with citrate pH 6.0. Incubation with antibody was overnight at 4°C 
at a 1:1000 dilution. As a second step we used Immunologic Poly-HRP-GAM/R/R IgG 
(DVPO110HRP) and Dako liquid DAB+ Substrate Chromogen System (K3468), followed by 
counterstaining with hematoxylin. Testis tissue was used as control. Slides were scored 
independently by two observers (JVMGB and YJ). Staining intensity (0 = absent, 1 = weak, 2 = 
moderate, 3 = strong) and extent of the staining (0 = 0%, 1 = 1-24%, 2 = 25-49%, 3 = 50-74% 
and 4 = 75-100%) were assessed. The two values were added to obtain sum scores. Cores 
where the tissue was lost were excluded from the analysis. To assess response to 
chemotherapy, patients were divided among good and poor responders. The histological 
response was assessed by determining the amount of necrotic tissue in the resection 
specimen obtained after chemotherapy. Response was considered good when a patient 
presented more than 90% necrotic tissue in the tumor, and bad responders were those with 
less than 90% necrosis[51]. 
 
Cell culture. Human osteosarcoma cell lines MOS, U2OS, 143B, ZK58,KPD, MNNG, MG-63 
and Saos-2 were previously described[52,53]. Cells were grown in RPMI1640 medium 
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supplemented with 10% fetal bovine serum and 25 U/mL penicillin and 25 µg/mL of 
penicillin-streptomycin.  All cells were cultured in a humidified incubator at 37°C with 5% 
CO2.  
 
siRNA screen. Transient knockdown of individual genes in U2OS cells was achieved using 
siRNAs from Dharmacon, GE (Landsmeer, Netherlands). The end concentration of siRNA was 
20nM and it was delivered to the cells with INTERFERin siRNA transfection reagent by 
reverse transfection according to the manufacturer’s procedures (Polyplus transfection, 
Leusden, Netherlands). The transfection was performed in u-clear 96-well plates from 
Corning. Nineteen Bcl-2 family members were targeted with a SMARTpool comprised of 4 
different siRNAs and with each single siRNA individually. After 24 hours of transfection the 
medium was refreshed and the cells were further incubated for 72 hours. Alamar Blue was 
acquired from Thermo Fisher Scientific (Bleiswijk, The Netherlands) and used to assess 
viability as specified by the manufacturer. Fluorescence was measured with a FluoStar 
Optima plate reader. 
 
Microarray data analysis. Gene expression profiles were obtained from a previously 
published microarray data set[54]. Using the Bioconductor lumi package, data was 
transformed with the variance stabilizing transformation algorithm and normalized with the 
robust spline normalization algorithm. Probe_ID identifiers from the Illumina Annotation for 
Illumina human-6 v2.0 expression beadchip were used as reporters (Bcl-xL reporter = 
ILMN_1654118). Kaplan Meier curves were created from the entry “Mixed Osteosarcoma-
Kuijer-127-vst-ilmnhwg6v2” in the web application R2 (http://r2.amc.nl). 
 
Immunoblotting. Cells were lysed with SDS protein buffer (125mM Tris/HCl pH 6.8, 20% 
glycerol, 4% SDS and 0.2% bromophenol blue). Proteins were resolved by SDS-PAGE and 
transferred to polyvinylidine difluoride membrane. Membranes were blocked in 5% BSA-
TBST (TRIS-0.05% Tween20), followed by overnight incubation with primary antibodies and 
45 minutes incubation with HRP-conjugated secondary antibodies. Chemoluminescence was 
detected with the bioimager LAS400  (GE Healthcare). 
 
Immunostaining. MOS and U2OS cells were transfected with siRNA as previously described. 
The cells were fixed 48 hours after transfection with ice cold methanol for 15 minutes, and 
were subsequently rinsed 3 times for 5 minutes with PBS. Afterwards, the cells were 
incubated with blocking solution [10% normal goat serum, 0.3%Triton100 in PBS] for 1 hour, 
rinsed 3 times for 5 minutes with PBS, and then incubated 1 hour with second 
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antibody(1:300). Nuclei stainig with Hoechst 33342 was performed as a final step together 
with the rinsing steps. The antibodies were diluted in antibody staining solution [1%BSA, 
0.3%Triton100 in PBS]. The cells probed mitochondria, were exposed to 75nM of 
MitoTracker® Red CMX Ros (from Cell Signaling) for 45 minutes previous to fixation. All 
images were taken with confocal microscope Eclipse Ti-E from Nikon. 
 
Cell viability, and real time apoptosis assays. For cell viability assays (excluding the siRNA 
screen), cells were processed using the ATPlite 1Step kit (Perkin Elmer) according to the 
manufacturer’s instructions, followed by luminescence measurement in a Fluostar Optima 
plate reader. Apoptosis was assessed by Annexin V staining and Caspase Glo3/7 (Promega). 
For real time Annexin V binding assays, cells were co-exposed to drugs and Annexin V in a u-
clear 96-well plate, and imaged every hour, for 66 hours. Images were obtained using a BD 
Pathway 855, then converted to videos, and Annexin V staining was quantified by an in-
house macro for Image-Pro Analyzer 7.0 as previously described[20].  For caspase 3/7 
activity measurements, cells were exposed to the drug for 24 hours after which the reagent 
was added 1:1. Luminescence was measured in a Fluostar Optima plate reader. 
 
Synergy assessment. To assess synergy, we used the Bliss independence model, which 
defines to what extent the effect of a drug at a certain concentration is independent of the 
presence of the other drug at a certain concentration[55]. This model predicts the combined 
response C for two single compounds with effects A and B: C = A+B – A*B[56].  
 
Statistical analysis. Dose response curve fitting and all statistical analyses were performed 
with GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA). The unpaired and paired two-
tailed t-test used to compare groups in Figure 3B and 3D was performed with IBM SPSS 
statistics 20. Event free survival was computed from the date of diagnosis until first 
recurrence, either local or metastatic. Tumors were divided into two groups, having low 
(mean sum score ≤3) or high Bcl-xL expression (mean sum score >3). Event free survival in 
both groups was compared using the Kaplan-Meier method and the Log-rank test with IBM 
SPSS statistics 20. 
 
RESULTS 
Identification of Bcl-xL as a critical pro-survival factor in osteosarcoma cells  
An siRNA screen was performed in U2OS cells to identify Bcl-2 family members required for 
osteosarcoma cell viability (See Fig. S1 for screen layout and results). The screen was 
54 
 
performed in duplicate with two negative controls, siGapdh and MOCK (only transfection 
reagent), and siKif11 as positive control (all controls were present in triplicate in each plate). 
Each value was normalized to siGapdh, which was set as 100% viability. MOCK transfected 
cells showed the same viability as siGapdh. To select hits causing loss of viability we 
calculated the standard deviation across each plate, and determined that a gene was a hit if 
the SMARTpool (comprised of 4 single siRNAs targeting the same gene) and the 4 single 
siRNAs tested individually, each were two standard deviations separated from siGapdh. 
Using this criteria 7 genes were selected, which included Bcl-B, Bak, Bid, Bfl-1, Mcl-1, Bok 
and Bcl-xL (Fig. 1A and B). To assess whether loss of viability was due to apoptosis, a caspase 
3/7 assay was performed. Caspase 3 and 7 are effector caspases that once activated, lead to 
cell death by cleaving important structural proteins, and causing DNA fragmentation and 
membrane blebbing[12]. Bcl-xL knockdown caused the highest caspase3/7 activity after 48 
hours of transfection indicating that it effectively triggered apoptosis (Fig. 1C).  
 
 




A) Average U2OS viability in wells transfected with siRNA SMARTpools targeting the indicated genes 
relative to siGapdh. Mean and standard deviation is shown. Horizontal line marks 2 SD threshold 
(<48.4% viability), hits are indicated in black, positive and negative controls in grey. B) Validated hits 
where all 4 single siRNAs mimic the SMARTpool and are below the threshold. Black bars represent 
the SMARTpool and grey patterned bars represent the single siRNAs. C) Caspase3/7 activity in U2OS 
cells transfected with SMARTpool siRNAs targeting the indicated genes. Values were normalized to 
control siGapdh. One representative experiment of two performed in quadruplicate is shown. Error 
bars represent standard deviation. 
 
 
Silencing Bak leads to autophagy in osteosarcoma cells 
Surprisingly, the screen also identified pro-apoptotic Bcl-2 family members, including Bak, 
Bid and Bok (Fig 1A-B). A caspase activity assay indicated that the loss of cell viability caused 
by siRNAs targeting these genes was not due to apoptosis (Fig 1C). It has been described that 
failure to activate apoptosis in Bak/Bax double knockout cells is accompanied by increased 
autophagy[13,14]. Autophagy is a recycling process that provides building blocks and energy 
during cell stress while unlimited autophagy leads to cell death[15].. We first assessed the 
knockdown efficiency of Bak in U2OS cells and confirmed a ~100% efficacy (Fig. 2A). Since 
there was no caspase 3/7 activation in response to Bak knockdown, we next determined if 
the observed loss of cells was due to slower proliferation. Phospho(ser10)-HistoneH3, a 
marker for cells in mitosis and Ki67, a marker for proliferating cells were analyzed in cell 
lysates and by immunocytochemistry, respectively. Silencing Bak in U2OS or MOS cells 
caused a reduction in phospho(ser10)-HistoneH3 levels  (Fig. 2B) and attenuated 
proliferation was confirmed by reduced Ki67 staining in si-Bak treated cells (Fig. 2C). 
 
To assess if Bak depletion triggered autophagy as shown in other systems[11,12], we 
determined the conjugation of the LC3 protein to phosphatidylethanolamine. This 
conjugation represents a critical step in the formation of the autophagosome, a double-
membrane organelle that engulfs cellular components during autophagy and subsequently 
fuse with the lysosome[16]. Silencing Bak in U2OS and in MOS cells led to accumulation of 
the conjugated form of LC3, termed LC3-II (Fig 2D). Moreover, treatment of U2OS cells in 
which Bak was silenced with 10µM chloroquine for 4 hours (chloroquine acidifies the 
phagosome inhibiting its fusion with the lysosome leading to autophagosome 
accumulation[17]) led to further accumulation of LC3 II (Fig 2E). In addition, 
immunocytochemistry showed that mitochondria no longer distributed throughout the 
cytoplasm but clustered perinuclearly in Bak-depleted cells where they colocalized with LC3-
marked autophagosomes (Fig. 2F). Together, these findings indicate that depletion of Bak in 
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Figure 2. Silencing Bak triggers autophagy in 
osteosarcoma cells. A) Western blot analysis of Bak 
knockdown efficiency in U2OS cells. B) Western blot 
analysis of phospho(ser10)-HistoneH3, total HistoneH3, 
and tubulin loading control in U2OS cells. C) Ki67 
staining in control (siGapdh) and siBak transfected U2OS 
cells 48 hours post-transfection (Ki67 antibody, green; 
Hoechst 33342, blue. D) Western blot analysis of LC3 
showing LC3-I (upper band) and –II forms in MOS and 
U2OS cells transiently transfected with siGapdh or siBak 
SMARTpools. E) Western blot analysis of LC3 in control 
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siBak SMARTpool and treated with or without 10µM chloroquine for 4 hours. F) Control MOS cells 
(MOCK) or MOS cells transiently transfected with siBak for 48 hours, exposed to MitoTracker® (red) 
for 45 min, fixed and stained with anti-LC3 (green), and Hoechst 33342 (blue). i, MitoTracker only; ii, 
merge of all three channels. 
 
 
Bcl-xL is expressed in osteosarcoma lung metastasis  
As Bcl-xL silencing caused severe loss of viability and led to the strongest induction of 
caspase 3/7 activity, we decided to further study its role in osteosarcoma. Others have 
reported that high Bcl-xL mRNA expression in osteosarcoma patients is correlated with lower 
overall survival rate [18]. We analyzed Bcl-xL mRNA expression using a previously published 
microarray data set of a cohort of 88 osteosarcoma patients but did not observe significant 
association with overall survival (Fig 3A). We next analyzed the expression of Bcl-xL by 
immunohistochemistry in 60 human primary osteosarcomas and 23 osteosarcoma lung 
metastases. Expression of Bcl-xL was detected in the majority of osteosarcoma samples and 
expression was higher in metastases compared to primary tumors (Fig. 3B,C). However, 
contrary to our expectations, high Bcl-xL protein expression levels (SUM score of intensity 
and % positive cells) in primary biopsies correlated with good response to therapy in this 
study (>90% necrosis post-chemotherapy) (Fig. 3D). Furthermore, event-free survival rates 
did not significantly differ between patients with high and low Bcl-xL expression in diagnostic 
biopsies (Fig. 3E). These results indicate that Bcl-xL is expressed in advanced osteosarcomas, 
but its expression is not correlated with poor therapy response or survival. 
 
Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma cells to chemotherapy 
Although we could not confirm earlier observations correlating Bcl-xL expression to patient 
survival, our siRNA screen indicated that Bcl-xL inhibition might enhance tumor killing in 
cases where it is expressed. Therefore, we assessed whether Bcl-xL represents a relevant 
target for osteosarcoma alone or in the context of conventional chemotherapy. First, four 
human osteosarcoma cell lines were treated with ABT-737, a BH3 mimetic that inhibits Bcl-
w, Bcl-xL and Bcl-2; of which only Bcl-xL was identified in the siRNA screen (Fig 1A). In 
addition, HA14-1, a selective Bcl-2 inhibitor was tested. All the cell lines showed loss of cell 
viability in the 10µM range for ABT-737 and at higher concentrations for HA14-1 (Fig. 4A and 
B). Subsequently, we asked if these inhibitors, when used at lower concentrations, could 
sensitize osteosarcoma cells to chemotherapy. The four osteosarcoma cell lines were co-
treated with a suboptimal concentration of ABT-737 and a dose range of doxorubicin for 72 
hours. At a concentration of 2.5 µM of ABT-737, viability of the cells was close to 100%. 
MOS, U2OS and to a lesser extent KPD and ZK58 showed increased sensitivity to treatment 
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with 50-500 nM doxorubicin under these conditions (Fig. 4C). By contrast, treatment with up 
to 10 µM of the Bcl-2 selective inhibitor, HA14-1 did not affect sensitivity to doxorubicin. 
Indeed, calculation of the deviation from additivity as predicted by Bliss independence 




Figure 3. Bcl-xL expression in osteo-
sarcoma clinical samples. A) Kaplan 
Meijer curve showing relation 
between Bcl-xL mRNA expression 
level and overall survival in a panel 
of 88 osteosarcoma patients. The 
cohort was divided into high and low 
expression at the median. The curve 
was made using http://r2.amc.nl. p 
value was deter-mined by 
Bonferroni testing.  
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B) Sum score (% plus intensity of staining) of Bcl-xL expression in all tumors included in the tissue 
microarray; average is shown in red.  Biopsies and metastases from the same patient are indicated in 
green (n=12); p-value determined by paired t-test. Unpaired biopsies (n=59) and metastases (n=7) 
are indicated in black; p-value determined by unpaired t-test. C) Representative images of Bcl-xL 
expression in primary osteosarcoma biopsy and metastasis. Images made with 40x Lens. D) Bcl-xL 
expression in biopsies of poor and good responders to chemotherapy. P-value determined by 
unpaired two-tailed t-test. E) Event free survival related to Bcl-xL expression in tissue microarray. 
Tumors were divided according to low (mean sum score ≤3; blue line (n=40)) or high Bcl-xL 




We next determined if synergy was due to enhanced apoptosis in the presence of the 
combination of ABT-737 and doxorubicin. For this purpose, real time imaging was used to 
detect labeled Annexin V binding to phosphatidylserine, a phospholipid that translocates to 
the outer lipid layer of the membrane when cells enter apoptosis [20]. In agreement with 
the viability assays (Fig 4C), ZK58 cells showed significant Annexin V labeling already in 
response to 2.5µM ABT-737 alone (Fig 5). However, in U2OS and KPD cells exposed to 2.5µM 
ABT-737 or 0.1µM doxorubicin alone, Annexin V labeling was absent or appeared at late 
time points after exposure whereas the combination of 2.5µM ABT-737 and 0.1µM 
doxorubicin caused rapid, strong Annexin V labeling. Moreover, this enhanced response to 
the combination of ABT-737 and chemotherapy was abolished in the presence of the pan-
caspase inhibitor z-VAD-fmk (Fig. 5). These results indicate that ABT-737, but not the Bcl-2 
selective inhibitor HA 14-1 can sensitize human osteosarcoma cells to chemotherapy leading 
to enhanced apoptosis. 
 
 Inhibition of Bcl-xL with WEHI-539 sensitizes osteosarcoma to doxorubicin 
To further pinpoint the sensitization to chemotherapy to inhibition of Bcl-xL, we made use of 
a recently developed Bcl-xL-selective BH3 mimetic, WEHI-539[21]. Exposing U2OS and MOS 
cells to this compound caused loss of viability at concentrations between 1-10µM and a 







Figure 4. Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma cells to chemotherapy. A,B) 
Dose response curve for ABT-737 (A) and HA14-1 (B) in the indicated human osteosarcoma cell lines. 
Error bars represent the standard deviation of two experiments performed in triplicate. Cells were 
exposed for 72 hours. C) Dose response curves for doxorubicin in the indicated osteosarcoma cell 
lines in absence (black circle) or presence of 2.5µM ABT-737 (red square) or 10µM HA14-1 (blue 
triangle). Cells were exposed for 72 hours. Error bars represent mean ± SEM of three experiments. D) 
Bar graph presenting the percentage of deviation from Bliss additivity based on data shown in C. One 







Figure 5. Inhibition of Bcl-xL in 
combination with doxorubicin 
leads to enhanced apoptosis. 
Live imaging of Annexin V 
accumulation in MOS, U2OS 
and ZK58 cells. Cells were 
treated with DMSO, 0.1µM 
Doxorubicin, 2.5µM ABT-737, 
or the combination with or 
without zvad-fmk as indicated. 
Graphs represent one of three 
independent experiments. 
Annexin V was quantified with 
ImagePro Analyzer 7.0. 
   
 
Moreover, a suboptimal dose of 1µM WEHI-539 effectively enhanced the response to low 
doses of doxorubicin in U2OS and MOS cells but showed no effect in KPD,ZK58, MNNG, MG-
63 and Saos-2. (Fig 6B). This difference could be attributed to differences in Bcl-xL 
expression: Bcl-xL protein levels were high in U2OS and MOS as compared to the other cell 
lines. (Fig 6C). Lastly, we investigated whether sensitization to doxorubicin in the presence of 
WEHI-539 was due to enhanced apoptosis. Indeed, MOS and U2OS cells exposed to 1µM 
WEHI-539 showed 2-3-fold higher induction of caspase 3/7 activity in response to 0.1µM 
doxorubicin, which by itself had little or no effect (Fig 6D). In agreement with the absence of 
synergy observed in KPD and ZK58 (Fig 6B), WEHI-539 failed to increase caspase activation in 
response to doxorubicin in these cells (Fig. 6D). Altogether, these findings demonstrate that 
osteosarcoma cells expressing Bcl-xL can be sensitized to chemotherapy through 
pharmacological Bcl-xL inhibition. 
 
DISCUSSION 
Patients with metastatic or recurrent osteosarcoma present low probability of survival 
mainly due to resistance to standard chemotherapy [22,23]. Bcl-2 family proteins play a 
crucial role in regulating cell survival/cell death pathways, and aberrations in their 
expression or function mediates tumor development and progression [24]. Our siRNA screen 
identifies anti-apoptosis genes such as Bcl-xL, Mcl-1 and Bfl-1, but interestingly, it also 
identified pro-apoptosis genes such as Bak, Bok and Bid. Autophagy was reported to be 







for the indicated osteosarcoma cell lines in absence (black circles) or presence of 1µM WEHI-539 (red 
squares). Cells were exposed for 72 hours. Mean ± SEM of three experiments is shown. C) Western 
blot analysis of Bcl-xL expression in the indicated osteosarcoma cell lines. D) Caspase 3/7 activity in 
the indicated osteosarcoma cell lines exposed to DMSO, 0.1µM doxorubicin, 1µM WEHI539 or the 
combination (mix). Mean ± SEM of three experiments is shown.  
 
 
knockout cells in response to death stimuli such as radiation and cytotoxic drugs [25,26]. 
Others have associated cell cycle arrest with Bak/Bax double knockout conditions [27,28]. 
We identify both aspects in Bak-silenced osteosarcoma cells: the cells proliferate slower and 
autophagy is activated. We also notice a recruitment of mitochondria to the perinuclear area 
where they colocalize with autophagosomes, which may point to mitoautophagy. 
Figure 6. Inhibition of Bcl-xL with 
WEHI-539 sensitizes osteosarcoma to 
doxorubicin. A) WEHI-539 dose 
response curves for the indicated 
human osteosarcoma cell lines. Cells 
were exposed for 72 hours. Error bars 
represent standard deviation of two 
experiments performed in triplicate. 
B) Doxorubicin dose response curves  
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Alternatively, this may reflect the recent demonstration that mitochondria can in fact 
contribute to the formation of the autophagosome membrane [29]. 
 
Bcl-xL expression has been associated with poor prognosis for patients with 
colorectal cancer[30] and hepatocellular carcinoma [31]. In colorectal cancer, high 
expression of Bcl-xL correlates with lymph node metastasis and poorer survival [32]. In 
melanoma the expression of Bcl-xL is correlated with tumor thickness and disease free 
survival [33], and in follicular lymphoma it is correlated with overall survival [34]. Bcl-xL 
expression has also been associated with resistance to cytotoxic agents in ovarian cancer 
[35]. Furthermore, the correlation between Bcl-xL expression and chemoresistance has been 
demonstrated in the NCI panel of 60 cell lines to be independent of p53 status [36]. 
 
In osteosarcoma, patients with high Bcl-xL mRNA levels have been reported to have a 
lower probability of 5-year overall survival [18]. We were not able to reproduce such a 
correlation in our dataset. Moreover, although in our study Bcl-xL protein was expressed in 
osteosarcoma biopsies and levels were higher in metastases, no correlation with poor 
response to chemotherapy was observed. The reason for this difference between our own 
observation and that of others[18] is currently unknown. Nevertheless, in line with the 
common role of anti-apoptotic Bcl-2 family members in cancer resistance to cytotoxic 
therapy [37,38] we find that Bcl-xL inhibition can sensitize osteosarcoma cells to low dose 
chemotherapy. 
 
ABT-737, a small molecule inhibitor of Bcl-xL, Bcl-2 and Bcl-w, was discovered in 2005 
and found to enhance the cytotoxic effect of chemotherapy and radiation [39]. Studies in 
myeloma cells [40], myeloid leukemias[41], neck-squamous cell carcinoma[42], 
gastrointestinal stromal tumor cells[43], and chondrosarcoma[38] indicated that ABT-737 
treatment sensitizes to chemotherapy and other cytotoxic agents [44]. We show that a 
similar strategy may be relevant in the context of human osteosarcoma. However, a major 
limitation for translation to the clinic is the fact that ABT-737 is not orally bioavailable, which 
limits flexibility of dosing regimens. ABT-263 is an analogue of ABT-737 with oral 
bioavailability, which also potently inhibits Bcl-xL, Bcl-2 and Bcl-w [45]. It has been 
demonstrated to have little activity as a single agent in a phase II clinical trial[46] but to 
enhance the effect of other cytotoxic agents [47-49]. The Bcl-xL-selective BH3 mimetic, 
WEHI-539 used in our current study has shown in vivo toxicity that hinders further clinical 
studies. Recently, a related Bcl-xL-selective inhibitor, A-1155463, has been synthesized 
lacking the toxic moiety [50]. Based on our current study, it will be of particular interest to 
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assess how such a pharmacological inhibitor affects the sensitivity of chemoresistant 
osteosarcomas. High Bcl-xL protein expression as detected by IHC may serve as a biomarker 
for treatment with Bcl-xL inhibitors alone or in the presence of chemotherapy. Such a 
strategy, would potentially allow reduced dosage of doxorubicin, thereby decreasing 
toxicity. Follow up preclinical studies, for instance using xenograft models, will have to 
determine efficacy and toxicity associated with different concentrations of Bcl-xL inhibitors, 
doxorubicin, and combinations. Our findings suggest that such studies are warranted to 
open the possibility for further clinical studies in patients with osteosarcoma. 
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Figure S1. Characterization of the siRNA screen. Raw values and plate layouts for siRNA screen using 
SMARTpool (sp) and single siRNAs (_1, _2, _3, _4) are shown. Mean and SD for positive (si-Kif11) and 
negative controls (siGapdh) are shown on the right and these values were used to calculate the 
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Background: Conventional high-grade osteosarcoma is the most common primary bone 
sarcoma with relatively high incidence in young people. Recurrent and metastatic tumors are 
difficult to treat. Methods: We performed a kinase inhibitor screen in two osteosarcoma cell 
lines, which identified MEK1/2 inhibitors. These inhibitors were further validated in a panel 
of six osteosarcoma cell lines. Western blot analysis was performed to assess ERK activity 
and efficacy of MEK inhibition. A 3D culture system was used to validate results from 2D 
monolayer cultures. Gene expression analysis was performed to identify differentially 
expressed gene signatures in sensitive and resistant cell lines. Activation of the AKT signaling 
network was explored using Western blot and pharmacological inhibition. 
Results: In the screen, Trametinib, AZD8330 and TAK-733 decreased cell viability by more 
than 50%. Validation in six osteosarcoma cell lines identified three cell lines as resistant and 
three as sensitive to the inhibitors. Western blot analysis of ERK activity revealed that 
sensitive lines had high constitutive ERK activity. Treatment with the three MEK inhibitors in 
a 3D culture system validated efficacy in inhibition of osteosarcoma viability. 
Conclusions: MEK1/2 inhibition represents a candidate treatment strategy for 


















Osteosarcoma is the most common primary malignant bone tumor occurring predominantly 
in children and adolescents, as well as in people older than 40 years of age. It is thought to 
arise from mesenchymal stem cells that are capable of producing osteoid(Anninga et al, 
2011; Rosenberg et al, 2013). At the moment of diagnosis, 10-20% of the patients present 
with metastasis. About 30-40% of the patients with localized osteosarcoma will present with 
relapse mainly as lung metastasis. Patients with recurrence have very poor prognosis with 
23-33% 5-year overall survival(Buddingh et al, 2010). Therefore, new effective therapies are 
urgently needed to improve the prognosis of osteosarcoma patients. 
Screening a kinase inhibitor library of pre-clinical or clinically approved drugs provides the 
possibility of identifying novel candidate treatments for osteosarcoma that can be translated 
to the clinic. In this study, we performed a kinase inhibitor screen in two osteosarcoma cell 
lines, and identified MEK inhibitors as possible therapeutic targets in cells with constitutive 
ERK activation.  
 
MATERIALS AND METHODS 
Reagents and antibodies. The kinase inhibitor library (L1200), Trametinib, AZD8330 and 
TAK-733 inhibitors were purchased from SelleckChem (Huissen, Netherlands). The ERK 
(9102), phospho(44/42)-ERK (137F5), phospho(Ser2448)-mTOR (D9C2), phospho(Ser473)-
AKT (#9271) and AKT (#9272) antibodies were from Cell Signaling (Bioké, Leiden, 
Netherlands). The antibody against tubulin (T-9026) was from Sigma Aldrich (Zwijndrecht, 
The Netherlands). 
 
Cell culture. Human osteosarcoma cell lines MOS, U2OS, 143B, ZK58, KPD and Saos-2 were 
previously described(Mohseny et al, 2011; Ottaviano et al, 2010). Cells were grown in 
RPMI1640 medium supplemented with 10% fetal bovine serum and 25 U/mL penicillin and 
25 µg/mL of penicillin-streptomycin.  All cells were cultured in a humidified incubator at 37°C 
with 5% CO2.  
 
Immunoblotting. Cells were lysed with SDS protein buffer (125mM Tris/HCl pH 6.8, 20% 
glycerol, 4% SDS and 0.2% bromophenol blue). Proteins were resolved by SDS-PAGE and 
transferred to polyvinylidine difluoride membrane. Membranes were blocked in 5% BSA-
TBST (TRIS-0.05% Tween20), followed by overnight incubation with primary antibodies and 
45 minutes incubation with HRP-conjugated secondary antibodies. Chemiluminescence was 




Cell viability and caspase3/7 activity. Cells were processed using the ATPlite 1Step kit 
(Perkin Elmer) according to the manufacturer’s instructions, followed by luminescence 
measurement on a plate reader. Caspase 3/7 activity was assessed with Caspase-Glo® 3/7 
from Promega (Leiden, The Netherlands) according to manufacturer’s protocol, and 
luminescence measurement on a plate reader. 
 
3D culture assay. MOS and U2OS cells were cultured in 384-well plates (Greiner μclear) in a 
hydrogel containing Matrigel (Beckton Dickinson) and collagen I, supporting invasive growth 
of both cell lines. Cells in culture were trypsinized and directly added to the cooled gel 
solution. Using a robotic liquid handler (CyBio Selma 96/60), 14.5μL of gel-cell suspension 
was transferred to each well of a 384-well plate (2000 cells/well). After polymerization for 30 
minutes at 37°C in an atmosphere of 5% CO2, growth medium was added on top of the gel. 
After 24 hours, the cells were exposed to the compounds in quadruplicate for a period of 72 
hours. For measuring cell viability in 3D, ATPlite was used as indicated by the manufacturer 
and luminescence was measured using a FluoroStar plate reader. Percentage viability was 
thereafter calculated by normalization of all conditions to DMSO. Results are presented as 
means ± SD. Images of 3D cultures were taken with a BD Pathway 855 (BD Biosciences). 
 
Pathway analysis. We used a previously published data of mRNA expression of 19 
osteosarcoma cell lines[Namlos et al PLoSOne 7, e48086, 2012] and performed a LIMMA 
analysis(Smyth, 2004) of sensitive (MOS, U2OS and 143b) versus resistant (KPD, ZK58 and 
Saos-2) cell lines(Kuijjer et al, 2012). We then ran a pre-ranked gene set enrichment 
analysis(Subramanian et al, 2005) using MSigDb v5.0 BioCarta (www.biocarta.com) 
signatures on the Benjamini and Hochberg False Discovery Rate corrected p-values obtained 
from LIMMA. Statistically significant signatures were defined as signatures with FDR<0.25. 
 
Statistical analysis. Dose response curve fitting and statistical analyses were performed with 









Kinase inhibitor screen for inhibition of osteosarcoma cell viability identifies MEK 
inhibitors 
A library composed of 273 
kinase inhibitors was used to 
screen for inhibitors that, as a 
single agent, decreased viability 
of osteosarcoma cells. MOS and 
U2OS were exposed to a 
concentration of 1µM for 72 
hours and viability was 
determined by measuring ATP 
production. Each screen was 
performed in duplicate with a 
goodness of fit (R2) of 0.8501 for 
the screen in MOS and 0.7981 in 
U2OS (Fig. 1A). All values were 
normalized to DMSO condition, 
and the candidates that exhibited 
less than 50% viability were 
considered a hit (Fig. 1B). Under 
this criterium, we identified 16 inhibitors in common for MOS and U2OS of which, six 
targeted the PI3K/mTOR pathway (BEZ235, GSK2126458, AZD8055, Torin 2, INK-128, PIK-75), 
six targeted the cell cycle (AT9283, BI2536, SNS-032, CHIR-124, dinaciclib and flavopiridol 
HCl), one targted Src (KX-391), one targeted Syk and Flt (R406 free base), and two were 
MEK1/2 inhibitors (Fig. 2A,B). The PI3K/mTOR pathway has been implicated in osteosarcoma 
cell survival and proliferation in vivo(Gobin et al, 2014). Dinaciclib and flavoripirol were 
previously reported to induce apoptosis in osteosarcoma cells(Fu et al, 2011; Li et al, 2007). 
Plk1 inhibition has been shown to cause cell death in osteosarcoma cells and its expression 
correlates with overall survival in osteosarcoma patients(Duan et al, 2010; Morales et al, 
2011; Yamaguchi et al, 2009). Here we focused on three MEK1/2 inhibitors: Trametinib and 
AZD8330, which were common in MOS and U2OS, and TAK-733, which was a hit in U2OS (in 
MOS treatment with TAK-733 showed 71% remaining viability). 
 
Figure 1. Kinase inhibitor screen in two human 
osteosarcoma cell lines. A) The screen was performed in 
MOS and U2OS cell lines in duplicate. The graphs 
represent the goodness of fit of the screens. B) All results 








MEK1/2 inhibition leads to apoptosis in cells with constitutive ERK activation 
The activity of these three inhibitors was tested using concentration ranges in six 
osteosarcoma cell lines: MOS, U2OS, KPD, ZK58, 143b and Saos-2 (Fig. 3A). All three 
inhibitors decreased viability of MOS and U2OS and strongly affected 143b. By contrast, 
viability of KPD, ZK58 and Saos-2 was not affected by any of the three inhibitors. A capase3/7 
activity assay confirmed that exposure to 0.5µM of each of the drugs induced apoptosis in 
MOS and U2OS, but not in KPD and ZK58 cells (Fig. 3B). 
Next, we asked if the observed differences in the response to MEK inhibition was related to 
the status of MEK activity, as measured by phosphorylation of the MEK target, ERK. Indeed, 
143b, which was the most sensitive cell line, is Ki-ras+ transformed (Sero et al, 2014) and 
showed the most prominent ERK phosphorylation, followed by the other two sensitive cell 
lines, MOS and U2OS (Fig. 4A). The resistant cell lines KPD, ZK58 and Saos-2 showed no 
Figure 2. Selection of hits in two 
human osteosarcoma cell lines. A) 
List of hits common to both cell 
lines (bold blue), only in MOS 
(green) and only in U2OS cells 
(black). B) Bar graphs representing 
the hits common to both cell lines, 
their viability score relative to 





constitutive ERK activation. Exposing MOS, U2OS and 143b to a concentration of 0.5µM of 
Trametinib, AZD8330 or TAK-733 for 6 hours, led to loss of ERK phosphorylation indicating 




Figure 3. Validation of three MEK inhibitors in 6 osteosarcoma cell lines. A) Dose response curves 
for Trametinib, AZD8330 and TAK-733 in 6 osteosarcoma cell lines as indicated. Cells were exposed 
for 72 hours. Each graph represents mean±s.e.m. of three replicates. B) Caspase 3/7 activity in 
presence of indicated inhibitors relative to DMSO in 4 osteosarcoma cell lines. The graph is a 







Figure 4. Western blot analysis of ERK phosphorylation in 6 osteosarcoma cell lines and effect of 
MEK inhibition. A) Western blot analysis of total ERK and phospho-ERK in 6 osteosarcoma cell lines.  
B) Western blot analysis of total ERK and phospho-ERK in MOS, U2OS and 143b osteosarcoma cell 
lines after 6 hours treatment with DMSO or 0.5µM of the indicated MEK inhibitors. 
 
 
Validation of MEK inhibition in a 3D cell culture system 
We made use of 3D cultures of identified sensitive and resistant cell lines to further validate 
the effect of Trametinib, AZD8330 and TAK-733. MOS, U2OS, KPD, and ZK58 were suspended 
in a collagen-matrigel mixture, and exposed 24 hours later to 0.5µM of each inhibitor for a 
period of 72 hours. As observed in 2D cultures, MOS and U2OS cells died in the presence of 
each of the three inhibitors whereas KPD and ZK58 were not affected (Fig. 5A,B). 
 
Potential mechanisms of resistance in cell lines not sensitive to MEK inhibition Our data 
indicated that MEK1/2 inhibition could be used to treat osteosarcomas that present with 
constitutive ERK activation but not in cases where MEK activity is low. Ras/Raf mutations are 
strong predictors for sensitivity to MEK inhibition(Jing et al, 2012; Solit et al, 2006) explaining 
sensitivity of 143b. We searched for mutations in exons or splice sites in the genes MEK1, 
MEK2, A-Raf, B-Raf, C-Raf, EGFR, FGFR, IGFR1, K-Ras, H-Ras and N-Ras in all cell lines used, 
employing a previously published method(van Eijk et al, 2011) but could not identify 
mutations that may explain high constitutive ERK phosphorylation in MOS or U2OS (data not 
shown).  
 
Next, we performed a pathway analysis on gene expression differences in sensitive (MOS, 
U2OS and 143b) versus resistant (KPD, ZK58 and Saos-2) cell lines(Kuijjer et al, 2012). This 
analysis revealed 7 signatures with enrichment of differentially expressed genes (Fig 6A). 





Figure 5. Validation of sensitivity to MEK inhibitors in a 3D culture system.  A) MOS, U2OS, KPD and 
ZK58 cells were re-suspended in a collagen-matrigel mix and 3D cultures were subsequently exposed 
to 0.5µM of the MEK inhibitors for 72 hours. Graphs are a representative experiment of two 
replicates, each performed in quadruplicate. Mean±s.d is shown. B) Representative images of 3D 
MOS cultures in absence or presence of Trametinib. 
 
 
upregulated in the resistant cell lines (Fig. 6B). However, Western blot analysis of phospho-
AKT(Ser473) showed active AKT in all cell lines except ZK58 (Fig. 6B). Similarly, mTOR, a 
downstream target of AKT signaling, was not differentially activated between sensitive and 
resistant cell lines (Fig. 6C). In agreement, all cell lines responded similarly to inhibition of 
AKT signaling using A674563 (inhibits AKT1 selectively) or AT7867 (inhibits AKT1/2/3) and 
were highly sensitive to a dual PI3K/mTOR inhibitor, BEZ235 (Fig. 6D). These data indicate 
that other differentially activated signaling pathways, rather than the predicted difference in 





Figure 6. Analysis of AKT pathway and its pharmacological inhibition. A) Plot representing the 7 
signatures that were significantly enriched (FDR< 0.25) in the cell lines resistant to MEK inhibition 
based on gene expression data. Pink/red represents the enrichment score (red>pink), and size 
represents the gene set size of the signature. B) Schematic representation of similarity between the 7 
signatures. Pink/red represents the enrichment score (red>pink), and the line width represents the 
number of genes shared between signatures.  C) Western blot analysis of total AKT, phosho(Ser473)-
AKT and phospho-(Ser2448)-mTOR in the indicated osteosarcoma cell lines. D) Dose response curves 
for the indicated AKT-mTOR inhibitors in the indicated osteosarcoma cell lines. Mean±s.d for 
experiment performed in triplicate is shown. 
 
DISCUSSION 
To identify new candidate avenues for therapeutic intervention for osteosarcoma we 
performed a kinase inhibitor screen in two human osteosarcoma cells lines. Our screen 
confirms previously reported findings (e.g. PI3K-AKT-mTOR inhibition), thereby validating 
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our screen. It also identifies new drugs in the context of osteosarcoma that are in the clinic 
for other malignancies and hence may be candidates for repurposing.  
 
PI3K-Akt-mTOR pathway is a network that controls many cellular processes such as 
cell proliferation, survival, metabolism and genomic integrity(Fruman & Rommel, 2014). It 
has been shown that osteosarcoma strongly depends on this pathway for cell survival and 
proliferation and pathway inhibition triggers cell death(Gupte et al, 2015; Perry et al, 2014). 
The expression of mTOR is correlated with event-free survival and cancer progression in 
osteosarcoma(Zhou et al, 2010). Our screen confirms mTOR signaling as a potential target to 
treat osteosarcoma.   
 
The main characteristic of tumor cells is uncontrolled cell proliferation and cell cycle 
regulators are key players in cancer growth. Our screen identifies several inhibitors targeting 
this hallmark of cancer, including inhibitors of cyclin-dependent kinases and spindle 
checkpoints. Cyclin-dependent kinases 2,4 and 6 are altered in 80-90% of tumors(Malumbres 
& Barbacid, 2001). In osteosarcoma, the Rb/p16/CDK4 axis is often deregulated with 
mutations or deletions in these genes(Mohseny et al, 2010; Wei et al, 1999).  Aurora and 
polo-like kinases are critical regulators of the mitotic spindle and have been implicated in 
various cancers(Fu et al, 2007). Several studies have shown that inhibition of Aurora kinases 
leads to cell death in osteosarcoma(Jiang et al, 2014; Tavanti et al, 2013). The Aurora kinase 
A inhibitor Alisertib (not present in our library) is undergoing testing in a phase II clinical trial 
of refractory solid tumors (NCT01154816). Inhibition of polo like kinase (Plk) 1 causes growth 
inhibition in various cancers(Bu et al, 2008; Reagan-Shaw & Ahmad, 2005). In osteosarcoma, 
Plk1 show higher expression in tumor samples compared to normal tissue, and its inhibition 
with NMS-P397 (not present in our library) leads to growth arrest and apoptosis(Sero et al, 
2014).  
 
The Ras-Raf-MEK-ERK mitogen activated protein kinase cascade is known to be 
involved in cell proliferation, apoptosis, differentiation and development. It integrates 
signals from cell surface receptors to activate ERK, which in turn enters the nucleus and 
activates transcription factors such as c-Myc, c-Fos, Ets, and Elk-1(Zhang & Liu, 2002). This 
pathway is often deregulated in tumors due to mutations or overexpression of upstream 
signaling components. B-Raf and Ras are frequently mutated in melanoma, colorectal 
cancer, ovarian cancer, lung cancer and pancreatic cancer among others (McCubrey et al, 
2007; Roberts & Der, 2007). In osteosarcoma, ERK pathway activity was reported to occur in 
67% of the cases analyzed, and mutations in B-RAF were only found in 13% of the 
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cohort(Pignochino et al, 2009). We identify three MEK inhibitors in the osteosarcoma cell 
viability screen: Trametinib is a selective allosteric inhibitor of MEK1/2 designed to treat 
tumor with overactive MEK-ERK pathway, which is found in tumors with B-Raf 
mutations(Abe et al, 2011). It was approved for melanoma, and it has also been tested in 
patients with pancreatic cancer, colorectal cancer and other solid tumors with B-Raf 
mutations(Wright & McCormack, 2013). AZD8330 and TAK-733 are two selective allosteric 
MEK1/2 inhibitors(Cohen et al, 2013; Dong et al, 2011). TAK-733 has shown good antitumor 
activity in melanoma cells(von Euw et al, 2012) as well as in human lung cancer(Ishino et al, 
2015).  
 
Our findings imply that MEK1/2 inhibition is a candidate approach to treat 
osteosarcomas harboring high ERK activity. Strikingly, while ERK phosphorylation status 
predicts sensitivity to MEK inhibition, mutation analysis of upstream components of this 
pathway does not identify candidate predictive mutations. Hence, ERK phosphorylation in 
tumor tissue as identified by immunohistochemistry may be a more accurate biomarker 
predicting sensitivity to MEK1/2 inhibitors than genomic analyses. We have not identified an 
alternative pathway selectively driving viability/growth of cell lines that are resistant to MEK 
inhibition. An enriched set of genes in the lines points to differential activation of the AKT 
pathway but based on AKT and mTOR phosphorylation status this pathway is active in all 
lines and, in agreement, all cell lines are similarly sensitive to AKT-mTOR inhibition. 
Interestingly, this indicates that three independent cell lines showing strong activity of MEK 
as well as AKT depend on the activity of both pathways. I.e., inhibition of either pathway is 
sufficient to cause loss of viability rather than these pathways compensating for each other.  
 
To our knowledge, we are the first to describe the efficacy of MEK inhibition in 
osteosarcoma cells with high ERK phosphorylation. Recently, a Phase I clinical trial 
(NCT02124772) started enrolling patients with solid tumors, including osteosarcoma, to 
study the efficacy of trametinib in combination with dabrafenib. In this setting, such 
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Conventional high-grade osteosarcoma is the most common primary bone malignancy with 
relatively high incidence in young people. About 40% of the patients develop metastases and 
have a very poor prognosis. New insights into osteosarcoma growth and progression that 
may lead to new therapeutic strategies are needed. Expression and activity of the Src 
cytoplasmic tyrosine kinase has been correlated with clinical stage and survival. Here, we 
studied the effect of pharmacological inhibitors of Src activity, including dasatinib, bosutinib 
and saracatinib in MOS and U2OS human osteosarcoma cell lines in 2D and 3D. All inhibitors 
decreased viability with an IC50 in the micromolar range. Likewise, treatment with each of 
the inhibitors reduced the IC50 of doxorubicin. However, only dasatinib treatment triggered 
caspase3/7 activation pointing to apoptosis. The selective activity of dasatinib correlated 
with its capacity to reduce Src activity. Next, the effects of the inhibitors were studied in 
MOS and U2OS cultures in 3D extracellular matrix (ECM) scaffolds. Under these conditions, 
all three inhibitors reduced viability but formation of branched networks in 3D ECM was 
selectively inhibited by dasatinib in presence of doxorubicin. The activity of focal adhesion 
kinase (FAK), a Src substrate that is important for cell migration, was exclusively sensitive to 
dasatinib. Indeed, in 3D ECM-embedded spheroid cultures dasatinib blocked cell migration 
capacity whereas the other inhibitors had no or partial effects. Together, these findings 
point to the use of dasatinib as a candidate drug  to enhance apoptosis in response to 





Osteosarcoma is the most common primary malignant bone tumor that arises from mesenchymal 
stem cells that are capable of producing osteoid[1]. It has an overall incidence of 3 cases per million 
annually occurring predominantly in children and adolescents, with a second peak in people above 
50 years of age[2]. At the moment of diagnosis, 10-20% of the patients present with metastasis, and 
about 30-40% of the patients with localized osteosarcoma will relapse mainly by presenting lung 
metastasis. Patients with relapsed disease have very poor prognosis with 23-33% 5-year overall 
survival[3].  
 
Src is a nonreceptor tyrosine kinase that belongs to a family of 11 members, and it is widely 
expressed in a most tissues. Src acts as signal transducer from cell membrane receptors to 
downstream substrates. Src activity regulates cell morphology, adhesion, and migration, as well as 
survival and proliferation through activation of PI3K-Akt, Ras-Raf-MEK-ERK, and Jak-Stat and a cell-
extracellular matrix (ECM) adhesion-signaling platform including the Src substrate focal adhesion 
kinase (FAK) [4,5]. Activation and expression of Src in colon cancer is associated with late tumor 
stage[6] and ability to metastasize[7]. Furthermore, Src activity and expression is also implicated in 
other malignancies such as breast cancer[8,9], ovarian cancer[10], lung cancer[11] and 
chondrosarcoma[12]. Notably, despite the fact that Src is overexpressed or constitutively active in 
many malignancies, mutations are rare in this gene. Therefore, in most cancers Src does not appear 
to drive tumor initiation or tumor formation, but may rather play a role in aspects of tumor 
progression[13,14].  
 
As mentioned above, Src transduces signal from cell receptors among which is IGFR. This 
receptor was reported to be highly expressed in high grade conventional osteosarcoma[15], and its 
inhibition with antibodies proofed to increase event free survival duration[16]. Additionally,, in 
osteosarcoma Src expression and activity has been shown to correlate with clinical stage and patient 
survival, making Src a potential aiding marker to determine prognosis in osteosarcoma[17]. All 
together, these findings leads us to investigate the inhibition of Src as potential treatment for 
patients with osteosarcoma. 
 
Dasatinib and bosutinib are two Src/Bcr-Abl inhibitors approved by the FDA for chronic 
myelogenous leukemia resistant to prior therapy[18-21]. Saracatinib, is a Src inhibitor that is 
currently in clinical trial for patients with recurrent osteosarcoma localized to the lung 
(NCT00752206), other cancers including melanoma (NCT00669019), prostate cancer (NCT01267266), 
and Alzheimer’s disease (NCT01864655). The compounds have been tested as single agents in solid 
tumors with no evident clinical activity[22-26]. Here, we assessed the capacity of these inhibitors to 
attenuate human osteosarcoma cell survival and migration in 2D and 3D environments. The 
inhibitors were tested alone or in combination with the clinically relevant chemotherapeutic 








MATERIALS AND METHODS 
Reagents and antibodies.  Doxorubicin was obtained from the Department of Clinical 
Pharmacology at LUMC, bosutinib, dasatinib and saracatinib were from SelleckChem 
(Huissen, Netherlands). Antibodies against ERK1/2(clone137F5), phospho-ERK(42/44) 
(#4695), AKT(9272), and phospho-AKT(Ser473) (#9271), were from Cell Signalling (Bioké, 
Leiden, The Netherlands). Antibodies against Src (clone GD11) and phospho-Src(Tyr418) 
(#44660G) were from Millipore (Amsterdam, The Netherlands) and Invitrogen (Bleiswijk, The 
Netherlands), respectively. Antibody against FAK (clone4.47) was from BioConnect (Huissen, 
The Netherlands). Antibodies against phospho-FAK(Tyr925) (#MBS8507066) and phospho-
FAK(Tyr861) (#MBS8507535) were from Biosourse (California, U.S.A.). Antibody against 
tubulin (T-9026) was from Sigma-Aldrich (Zwijndrecht, Netherlands).  
 
Cell culture. Human osteosarcoma cell lines MOS, U2OS were previously described[27,28]. 
Cells were grown in RPMI1640 medium supplemented with 10% fetal bovine serum and 25 
U/mL penicillin and 25 µg/mL of penicillin-streptomycin.  All cells were cultured in a 
humidified incubator at 37°C with 5% CO2.  
 
Western blotting. Cells were lysed with SDS protein buffer (125mM Tris/HCl pH 6.8, 20% 
glycerol, 4% SDS and 0.2% bromophenol blue). Proteins were resolved by SDS-PAGE and 
transferred to polyvinylidine difluoride membrane. Membranes were blocked in 5% BSA-
TBST (TRIS-0.05% Tween20), followed by overnight incubation with primary antibodies and 
45 minutes incubation with HRP-conjugated secondary antibodies. Chemoluminescence was 
detected with a bioimager, LAS400 (GE Healthcare). 
 
Measuring cell viability and apoptosis in 2D cultures. For cell viability, cells were processed 
using the ATPlite 1Step kit (Perkin Elmer) according to the manufacturer’s instructions, 
followed by luminescence measurement. Apoptosis was measured by assessing caspase3/7 
activity with CaspaseGlo 3/7 (Promega). The cells were exposed to the drug for 24 hours 





3D collagen/matrigel culture assay. U2OS and MOS cells were cultured in 384-well plates 
(Greiner μclear) in a hydrogel containing Matrigel (Beckton Dickinson) and collagen I, 
supporting invasive growth of both cell lines. Cells in culture were trypsinized and directly 
added to the cooled gel solution. Using a robotic liquid handler (CyBio Selma 96/60), 14.5μL 
of gel-cell suspension was transferred to each well of a 384-well plate (2000 cells/well). After 
polymerization for 30 minutes at 37°C in an atmosphere of 5% CO2, growth medium was 
added on top of the gel. After three days, when the cells had formed a network structure, 
compounds were diluted and added in quadruplicate wells for a period of 72 hours. 
For measuring cell viability in 3D, a solution of 7g/L WST-1 (Serva Electrophoresis) 
and 8mg/L phenazinium methylsulfate (PMS; Sigma Aldrich) in 1x PBS were mixed in a 1:1 
ratio and 5μL was added to each well. Plates were placed at 37°C for 5 hours, after which the 
absorbance at 450nm was measured using a FluoStar Optima late reader. Percentage 
viability was thereafter calculated by robust normalization (median) of the plates between 
positive control (no cells; 0% viability) and negative control (solvent; 100% viability) 
conditions. 
For imaging, cells were fixed using 3.7% Formaldehyde (Sigma-Aldrich), 
permeabilized with 0.1% Triton-X100 and stained for F-actin using 50nM Rhodamine-
Phalloidin (Sigma Aldrich) for 12 hours at 4˚C. Subsequently, the plates were washed in PBS 
for at least 24 hours at 4˚C. The plates were then imaged on a BD Pathway 855 inverted 
fluorescence microscope (BD Biosciences) using a 4x lens to capture Rhodamine-Phalloidin 
staining at focal planes spaced 50µm throughout the gel, capturing approximately 70% of a 
well. Subsequently, maximum intensity projections of the in-focus information of the Z-
stacks was made using OcellO (OcellO B.V., Leiden, The Netherlands) image analysis tools. 
 
3D collagen spheroid assay. Cell suspensions were injected into collagen scaffolds using 
automated injection as previously described[29,30]. 1 mg/ml rat tail collagen was prepared 
in complete growth medium supplemented with 1:5 dilution of 0.44M NaHCO3 and 1:10 
dilution of 1M Hepes pH 7.4. 60µL was added to each well of a 96-well μ-clear plate 
(Corning) and incubated for 1 hour at 37ºC to allow polymerization. Cells were collected in 
medium containing 2% PVP, transferred to a needle and droplets of ~8nL were injected into 
the collagen gels resulting in spheroids of ~300μm diameter, using injection robotics from 
Life Science Methods, Leiden NL (http://www.lifesciencemethods.com). For DIC imaging of 
spheroids, a Nikon confocal microscope was used. 
 
Statistical analysis. Dose response curve fitting and all statistical analyses were performed 
with GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA). The unpaired two-tailed t-test 
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was used to compare between groups. Significant difference between groups in the 3D assay 




Reduced human osteosarcoma cell viability in presence of bosutinib, dasatinib and 
saracatinib and selective Src kinase inactivation by dasatinib 
We determined the effect of dasatinib, bosutinib and saracatinib on cell viability in MOS and 
U2OS human osteosarcoma cells. Responses to these inhibitors were highly similar for MOS 
and U2OS cells but differed considerably between the different inhibitors  (Fig. 1A). Both cell 
lines showed no response to bosutinib concentrations <1 µM and a rapid decline in viability 
was observed as the bosutinib concentration increased from 1 to 5 µM. Instead, viability 
gradually decreased in response to 0.1-10 µM dasatinib and a similar trend, albeit less 
effective, was observed for saracatinib. IC50 for bosutinib and dasatinib was ~5 µM and IC50 
was >10 µM for saracatinib (Fig 1B). 
 
PI3K/AKT and Raf-MEK-ERK MAP kinase signaling pathways represent important drivers of 
survival and proliferation in many different cancer types. These two pathways are regulated 
by Src activity[31,32].  We tested if treatment of MOS and U2OS cells with the Src inhibitors 
affected these pathways. However, treatment with up to 2.5µM bosutinib, dasatinib, or 
saracatinib did not affect phosphorylation of ERK (Fig 1C). In fact, treatment with saracatinib 
increased the levels of ERK phosphorylation particularly in U2OS. On the other hand, 
dasatinib and saracatinib suppressed AKT phosphorylation at 2.5µM whereas bosutinib had 
no effect. Moreover, while 1µM dasatinib effectively attenuated Src phosphorylation at Y418 
in both cell lines, indicating attenuated Src kinase activity, bosutinib and saracatinib failed to 






Figure 1. Effect of dasatinib, bosutinib and saracatinib in human osteosarcoma cells. 
A) Dose response curves for dasatinib, bosutinib and saracatinib in two human osteosarcoma cell 
lines. Error bars represent the standard deviation of three experiments performed in triplicate. Cells 
were exposed for 72 hours. B) Table with IC50 values of bosutinib, dasatinib and saracatinib in MOAS 
and U2OS cells. C) Western blot analysis of phospho-ERK(p44/42), total ERK, phospho-AKT(Ser473), 
total AKT, phospho-Src(Tyr418), total Src, and tubulin loading control in MOS and U2OS cells under 
control (DMSO) conditions or after 48 hours treatment with 1 or 2.5µM of the indicated inhibitors. 
 
Sensitization to doxorubicin in presence of bosutinib, dasatinib and saracatinib and 
selective induction of apoptosis by dasatinib 
Src kinase activity may not be a bona fide cancer driver and mono therapy using either of 






Figure 2. Effect of dasatinib, bosutinib and saracatinib in human osteosarcoma cells in the context 
of doxorubicin. A). Dose response curves for doxorubicin in two human osteosarcoma cell lines in 
absence (black) or presence of 1µM of dasatinib (red), bosutinib (green) or saracatinib (blue). Cells 
were exposed for 72 hours. Error bars represent mean ± SEM of three experiments B). Table with 
IC50 values for doxorubicin alone (DMSO) or in combination with 1µM bosutinib, dasatinib or 
saracatinib in MOS and U2OS cells. C) Caspase 3/7 activity in two human osteosarcoma cell lines 
under control conditions (white bars) or upon exposure for 24 hours to 0.1µM doxorubicin (black 
bars) in the presence of DMSO or 1µM dasatinib, bosutinib and saracatinib as indicated. Mean ± S.D 
is shown for one representative experiment of 3 performed in triplicate.  
 
signaling pathways[13,14]. Its inhibition may render tumor cells more sensitive to 
chemotherapy. To investigate this, MOS and U2OS cells were exposed to 1µM of the 
inhibitor together with a dose range of doxorubicin for 72 hours. Indeed, both cell lines 
showed a reduction in viability already at lower doses of doxorubicin in presence of 
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dasatinib, bosutinib, or saracatinib, as compared to the response to doxorubicin alone (Fig. 
2A). For MOS cells, the IC50 for doxorubicin was reduced by 30-50%, and for U2OS cells a 
reduction of 50-80% was observed (Fig 2B). In order to assess whether decreased viability 
was related to apoptosis, we determined caspse3/7 activity. Interestingly, only treatment 
with dasatinib led to apoptosis either alone (not shown) or in combination with doxorubicin 
(Fig. 2C). 
 
Reduced human osteosarcoma cell viability in 3D cultures in presence of bosutinib, 
dasatinib and saracatinib and selective morphological effects induced by dasatinib. 
Next, we analyzed the effect of the panel of Src inhibitors in a 3D in vitro culture model. 
MOS and U2OS cells were suspended in a collagen-matrigel mixture and allowed to form a 
multicellular network for 72 hours. Subsequently cells were exposed to 1µM of dasatinib, 
bosutinib, or saracatinib alone or combined with a concentration range of doxorubicin. 
Inhibition of cell viability by the inhibitors alone as measured biochemically, was more 
pronounced compared to effects measured in 2D. All three inhibitors by themselves caused 
a reduction in viability of 40-50% (Fig 3A). Additional treatment with doxorubicin further 
decreased viability but no synergy was observed between doxorubicin and any of the 
inhibitors.  
Next we used imaging and image analysis algorithms to measure “branch length” and 
“solidity” or roundness of the multicellular structures; parameters correlated cell migration 
[33]. Low concentrations of doxorubicin up to 0.1µM did not affect these parameters (Fig 
3B).  Exposure to 1µM of the Src inhibitors alone led to decreased branch length and 
increased solidity. However, in the presence of dasatinib MOS and U2OS cells were 
selectively responsive to low concentrations of doxorubicin; showing a decrease in branch 
length and a concomitant increase in solidity of the multicellular structures (Fig. 3B-D). 
 
Selective inhibition of FAK activity and 3D osteosarcoma cell migration by dasatinib  
To further investigate morphological effects caused by these inhibitors that may impact on 
osteosarcoma progression we made use of a 3D spheroid model. MOS and U2OS cells were 






Figure 3. Effect of dasatinib, bosutinib and saracatinib in human osteosarcoma cells in the context 
of doxorubicin in 3D cultures. A,B) Doxorubicin dose response curve for human osteosarcoma cells 
grown in collagen/matrigel mixture under control conditions (DMSO; black line) or in presence of 
1µM dasatinib (red), bosutinib (green), or saracatinib (blue). Cells were exposed for 72 hours. A) 
Viability was assessed using WST/PMS absorbance. Error bars represent mean ± SEM of three 
experiments. Values were normalized to median of DMSO. B) Image analysis was used to assess 
average branch length (top graphs) and solidity (bottom graphs). Error bars represent mean±s.d of 
one representative experiment done in quadruplicate. C) Representative images such as those used 
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Figure 4. Dasatinib 
inhibits Fak activation 
and stops collagen 
invasion in 
osteosarcoma. A) 




injection (0 hours) and 
after 72 hours 
incubation under 
control conditions 
(DMSO) or in presence 
of 1µM of the indicated 
inhibitors. Images were 
obtained using a Nikon 
confocal microscope. 
B) Western blot 
analysis of total FAK 
and phospho-
Fak(Tyr397), (Tyr861), 
(Tyr925), and tubulin 
loading control for 
U2OS and MOS cells 
maintained for 48 
hours under control 
conditions (DMSO) or 




for graphs in B. Each image is a compression of 11stacks of the 3D culture. D) Zoom-in of selected 






were exposed to DMSO or 1µM bosutinib, dasatinib and saracatinib for 72hours. Saracatinib 
did not affect spheroid outgrowth or 3D cell migration and bosutinib had an intermediate 
effect while dasatinib treatment completely blocked outgrowth and collagen invasion of 




Src promotes invasion and metastasis and plays a key role as a regulator of cell-ECM 
adhesions containing the Src substrate FAK. The Src/FAK complex integrates signals from the 
extracellular environment and controls and coordinates adhesion dynamics and cell 
migration[34,35]. FAK is autophosphorylated at Tyr397 upon integrin-mediated adhesion 
creating a binding site for Src, which subsequently phosphorylates FAK at Tyr407, 576, 577, 
861 and 925[34,36]. We analyzed FAK phosphorylation after 48hour treatment with 1µM 
dasatinib, bosutinib or saracatinib. The FAK autophosphorylation site was not affected by 
any of the inhibitors. However, in agreement with its selective inhibition of cell migration 
through 3D ECM scaffolds, phosphorylation of FAK at Src substrates Tyr861 and Tyr925 was 
selectively inhibited by dasatinib. Whereas Saracatinib and bosutinib had no apparent effect 




It this study we investigated the effect of Src inhibitors dasatinib, bosutinib, and saracatinib 
in two human osteosarcoma cell lines. Impacts on cell viability and migration were tested as 
single agent as well as in combination with the chemotherapeutic compound doxorubicin, 
which is used in the clinic for treatment of osteosarcoma. Src activity regulates the PI3K-Akt, 
Ras-Raf-ERK, Jak-Stat and FAK-Paxillin pathways. In osteosarcoma, none of the inhibitors 
interfered with ERK and AKT phosphorylation, and only dasatinib inhibited Src and Fak 
activation in MOS and U2OS cell lines. Notably, the inhibitors have other targets such as 
other members of the Src family, Bcr-Abl, MAPK kinases, Eph receptors, cKit, STK6, PDGFR 
and TEC family kinases[37,38]. An interesting study that mapped the target profile of 
bosutinib in chronic myeloid leukemia cells identified new targets and to what extent targets 
were inhibited[39]. The MAPK family was found to be a major target, but MEK1 and MEK2 
were not significantly inhibited[39,40]. These results may explain why ERK activation was not 
inhibited by any of the inhibitors in our study. Furthermore, the fact these inhibitors do not 
completely inhibit the activity of a kinase, can explain why saracatinib and bosutinib did not 
show appreciable inhibition of Fak phosphorylation, and failed to affect cell migration. The 
autophosphorylation site (Tyr397) of Fak causes a conformational change allowing Src 
binding and further Fak phosphorylation in Tyr576/577, Tyr861 and Tyr925. The 
phosphorylation of these sites is important for the interaction with integrins and E-
cadherin[34]. While bosutinib has been reported to inhibit Fak-(Y925) phosphorylation in 
breast cancer cells, in the two osteosarcoma cell lines used only dasatinib inhibited Src-




To study the effect of dasatinib, bosutinib or saracatinib on the migratory behavior of 
osteosarcoma cells, we used 3D cell culture systems. 3D cultures may better reflect the 
tumor microenvironment as compared to 2D cultures and cell matrix adhesions and 
migratory behavior are closer to the in vivo situation [42-45]. In the two 3D systems we 
used, including mixture of cells in collagen/matrigel and microinjection of cells to examine 
migration from spheroids in collagen gels, collagen type I is the major ECM component and 
this is also the main component (90%) of the ECM of bones[46]. Our finding that dasatinib 
selectively blocks osteosarcoma cell migration in this environment correlates its selective 
inhibition of Src-mediated Fak phosphorylation. Thus, dasatinib treatment likely interferes 
with the Src/Fak signaling platform to prevent cell migration and may thus interfere with 
metastatic capacity. 
 
In addition, dasatinib selectively triggers apoptosis and causes morphological 
alterations in 3D cultures in the presence of doxorubicin. It was previously reported that 
dasatinib has the capacity to sensitize chondrosarcoma cells to doxorubicin (jolieke refe). 
Furthermore, a new Src inhibitor, A-770041, was shown to increase sensitivity to 
doxorubicin in osteosarcoma cells (refDuan et al. BMC Cancer 2014, 14:681). Notably, a 
decrease in the IC50 of doxorubicin is observed when combined with each the inhibitors 
indicating that dasatinib selectively affects some, but not all aspects of these inhibitors. 
Several studies have hown that these three inhibitors do not have an effect as single agents 
in solid tumors. For example, dasatinib inhibits activation of Src and Fak in vitro and in vivo, 
but it does not induce apoptosis or prevent tumor metastasis to the lungs in a xenograft 
osteosarcoma mice[47]. However, others showed that for biliary tract carcinomas 
saracatinib was effective in a preclinical model, and both dasatinib and saracatinib are 
effective in leukemia[48-51] indicating that the therapeutic effect of these inhibitors is 
cancer type-dependent. Despite the lack of activity as a single agent, the combination of 
dasatinib, bosutinib or saracatinib with doxorubicin in breast cancer or pancreatic cancer 
cells did lead to a synergistic effect in vitro and in vivo[52-54]. 
 
Altogether, we find that dasatinib selectively inhibits activity of the Src/Fak signaling 
complex in osteosarcoma cells and, most likely as a consequence of this, migration in 
collagen scaffolds. Furthermore, while all three inhibitors decreased the IC50 of doxorubicin, 
dasatinib selectively triggers apoptosis and morphological changes in the context of 
doxorubicin. Our findings point to the combination of dasatinib and doxorubicin as a 
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Osteosarcoma is the most common primary malignant bone sarcoma occurring 
predominantly in children and adolescents, and a second peak at middle age. It is 
characterized for being highly metastatic and resistant to chemotherapy, which gives these 
patients very poor prognosis.1,2  
Before the introduction of chemotherapy, patients with osteosarcoma had a low 
chance of surviving this tumor. Once it was introduced, their prognosis increased 
dramatically, however, it has reached plateau. To address this challenge, there have been 
many clinical trials with the goal to find the best combination of chemotherapeutic agents 
that can increase the overall survival rate.3,4 However, until now, there has been no further 
improvement. New efforts are being made to find new drug targets such as kinases or 
signaling pathways of the immune system. Many clinical trials testing these new molecules 
have shown that single agent therapies are not effective. 
The aim of this thesis was to find new strategies to reduce osteosarcoma viability or 
that could potentiate the effect of doxorubicin. These findings, if translated to the clinic, 
would allow the use of lower doses of doxorubicin and avoid serious side effects that 
compromise the patient’s life. I used a variety of techniques including high-throughput 
screening using siRNA and inhibitor libraries, which led to the discovery of new potential 
treatments. 
Cell lines 
Cancer cell lines derived from tumors are the most common tumor used in cancer research, 
and it has been of tremendous value in the field. There are doubts about how representative 
they are of the tumors they came from, and many research groups have made efforts to 
identify cell lines which are most represent the type of tumor they come from.5–7 However, 
it has been also been shown for 127 cancer cell lines, that when injected in nude mice, they 
all formed a tumor which resembled histologically the cancer type.8 Additionally, cancer cell 
lines retain the genotype of the original tumor such as mutations and expression of a 
characteristic gene.9 
In this thesis I used osteosarcoma cell lines that have fully characterized by Mohseny 
A, et al. All of the cell lines had the capacity to differentiate in vitro into at least one of the 
three histological subtypes of osteosarcoma. However, not all of them had the capacity to 
form tumor in nude mice.10 The cell lines employed in these studies, were chosen based on 
the genetic profile of p53 and CDKN2A, which are two of the well-known altered genes in 
osteosarcoma.11  Additionally, the identity of cell lines was confirmed using the Cell ID 
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GenePrint 10 system (Promega Benelux BV, Leiden, The Netherlands) before and after 
completion of the experiments, and mycoplasma tests were performed on a regular basis. 
Targeting the cell cycle 
The DNA Damage Response (DDR) is evolutionary conserved and essential to ensure the 
faithful maintenance and replication of the genome. This signaling cascade senses DNA 
damage and triggers repair, cell cycle arrest and, in case of severe damage, cell death.12 
Chemotherapeutic drugs such as doxorubicin cause DNA double strand breaks, DNA 
alkylation, topoisomerase inhibition II among many other mechanisms.13 This type of DNA 
lesions activate the DDR which lead to cell cycle arrest allowing the tumor cells to repair the 
damage and continue dividing. In Chapter 2, I proposed Aven to be a new regulator of DNA 
damage response showing that it is a key regulator of ATR-Chk1 axis. Subsequently, I 
investigated the effect of CHK1 inhibition in combination with doxorubicin. For the first time 
in osteosarcoma, these findings indicate that abrogation of Chk1 signaling using clinically 
relevant drugs may be combined with chemotherapy to treat osteosarcoma more 
effectively. Cancer cell cycle deregulation is often caused by altered CDK activity.14 
Furthermore, osteosarcoma is characterized by alterations in Rb protein and CDK4, which 
leads to uncontrolled cell cycle progression. In Chapter 3 a screen of kinase inhibitors 
revealed that osteosarcoma cells are sensitive to inhibitors targeting kinases that regulate 
the cell cycle among others. Overall, I show that osteosarcoma is highly dependent on the 
cell cycle kinases to proliferate, and this signaling network is a potential therapeutic target. 
 
3D cultures  
Tumors are a complex disease that is governed by many intracellular signals such as gain of 
function of oncogenes, loss of function of tumor suppressors and mutations in key proteins. 
However, tumor cells are also influenced by the extracellular environment such as cell-
matrix and cell-cell interactions. 2D mono-layer cultures have been a powerful tool but it 
was shown that the cells divide abnormally, change shape and physiological behavior.15,16 3D 
culture models provide a platform in which the tumor cells can behave more like the real 
tumor, and can be used to study cell viability and metastatic behavior after treatment with 
inhibitors.  
 
Throughout the whole thesis I set out to find approved or preclinical inhibitors, which 
were effective alone or in combination with doxorubicin. In Chapter 2,4,5 I assessed viability 
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of the treated cells in 2D monolayer cultures, and validated these results in 3D culture 
models.  
 
Importance of inhibiting migration 
Ostesarcoma is a highly metastatic tumor and at the moment of diagnosis, 10-20% of the 
patients already present with metastasis. About 30-40% of the patients with localized 
osteosarcoma will relapse mainly by presenting lung metastasis. Patients with recurrence 
have very poor prognosis with 23-33% 5-year overall survival.17,18  
 
Tumor cell migration to distant locations has already occurred in patients with 
metastases implicating that cell migration is not a therapeutically relevant aspect of tumor 
progression. However, it has been shown that short range-migration (dispersal) to adjacent 
sites affects tumor topology and growth rates. This is the case in primary tumors and 
metastatic tumors. Although the tumor origin is genetically homogeneous, clonal variations 
arise that change the fate of these cells leading to resistance to treatment, and regrowth of 
the tumor after months of the treatments. Recent modeling approaches have shown that 
short-range dispersal contributes to cell mixing inside the tumor and targeting cell migration 
could in fact considerably suppress tumor growth.19 In Chapter 5 I used two 3D models to 
study the inhibition of migration using dasatinib, saracatnib and bosutinib. Using the 
spheroid collagen injection model, dasatinib was the only inhibitor capable of containing the 
cells in the spheroid; it inhibited migration completely. In the other 3D model employed 
here, the cells were re-suspended as single cells in a collagen-matrigel mix allowing me to 
study their morphology under treatment conditions. In this case I exposed these cells to 
doxorubicin in combination with the inhibitors mentioned above. Strikingly, only the 
combination of dasatinib and doxorubicin induced the retraction of branches and a round 
shape morphology. These two experiments confirm each other, and indicate that dasatinib 
in combination with doxorubicin is an effective targeted therapy that may avoid recurrence. 
Doxorubicin together with dasatinib is a potential candidate for further clinical studies.  
 
Signaling pathways involved in osteosarcoma cell survival 
 
PI3K-Akt-mTOR pathway is a network that controls many cellular processes such as cell 
proliferation, survival, metabolism and genomic integrity.20 The expression of mTOR is 
correlated with event-free survival and cancer progression in osteosarcoma21. A kinase 
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inhibitor screen described in chapter 4 indicated PI3K/mTOR pathway as crucial: 37% of the 
hits were inhibitors that targeted this pathway. Another relevant signaling network for 
osteosarcoma is the cell cycle with 37% of the hits inhibiting kinases in this pathway, such as 
aurora kinases, Chk1, CDKs and Plk1.   
The Ras-Raf-MEK-ERK mitogen activated protein kinase cascade is known to be 
involved in cell proliferation, survival, differentiation and development. It integrates signals 
from cell surface receptors that activate MEK, which will activate ERK. Once ERK  is activated, 
it enters the nucleus and activates transcription factors such as c-Myc, c-Fos, Ets, and Elk-1.22  
In osteosarcoma, ERK pathway activity was reported to occur in 67% of the cases analyzed.23 
In chapter 4, I identified three MEK inhibitors in a screen, which led me to further investigate 
this pathway. Although no genomic or transcriptomic changes in the MEK pathway 
discriminated sensitive from insensitive cell lines, I could show that MEK inhibitors are only 
effective in cells where relatively high ERK activity can be detected. Thus, active, 
phosphorylated ERK (that may be detected by immunohistochemistry in clinical samples) 
may serve as a biomarker for treatment with MEK inhibitors.  
In Chapter 3 I investigated the anti-apoptotic protein Bcl-xL. The expression of Bcl-xL 
did not correlate with survival, but in osteosarcoma cells the inhibition of Bcl-xL did 
potentiate the effect of doxorubicin. Furthermore, it has been shown that Bcl-xL expression 
is dependent on ERK activity.24,25  Strikingly, the osteosarcoma cell lines sensitive to MEK 
inhibition were also the ones with highest Bcl-xL expression and more sensitive to Bcl-xL 
inhibition. These results suggest that ERK expression could also be used as a marker for this 
strategy, pointing to a more personalized treatment. 
 
Future perspectives 
In this thesis I described several possible therapies to treat patients with osteosarcoma. 
These results come from in vitro studies, and must be tested in osteosarcoma animal models 
to be translated to the clinic. Mouse models are commonly used because of the close 
genetic and physiological resemblance to that of humans, and the ease with which they can 
be genetically modified to facilitate tumor formation.26,27 Genetically engineered mouse 
models with p53 and Rb deletions in the osteoblasts effectively induce osteosarcoma 
formation that resembles human osteosarcomas.28 Another possible mouse model involves 
overexpression of c-fos and c-jun proto-oncogenes, which induces the formation of 
osteosarcoma.29 This model allows the spontaneous formation of osteosarcomas that can be 
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used to validate novel treatments. Alternatives to genetic mouse models for further 
investigation of drugs and drug combinations used in this thesis include mouse or zebrafish 
xenografts with patient materials or patient-derived osteosarcomas cultured in a 3D collagen 
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Osteosarcoma: searching for new treatment options 
 
Osteosarcoma is the most frequent high-grade primary malignant bone tumor that is 
thought to arise from mesenchymal stem cells with the capacity to produce osteoid. The 
overall incidence is of three cases per million annually, and it occurs predominantly in 
children and adolescents as well as in people over 50 years of age.  
Currently, the treatment consists of preoperative chemotherapy followed by 
resection of the tumor. The most effective systemic chemotherapeutics are cisplatin, 
doxorubicin and methotrexate. Despite extensive studies aimed at finding optimal combined 
chemotherapeutic strategies, overall 5-year survival rates have not increased above 70%, 
and around 35-45% of the patients have tumors that do not respond to chemotherapy. 
The aim of this thesis was to discover new therapeutic options for osteosarcoma 
patients. I focused on finding candidate targets and pharmaceutical inhibitors for killing 
human osteosarcoma cells or for sensitizing osteosarcoma cells to doxorubicin. In Chapter 2 
I studied Aven, an adaptor protein that has been implicated in anti-apoptotic signaling and in 
DNA damage response signaling.  The expression of Aven is inversely correlated with 
metastasis-free survival in osteosarcoma patients, and is increased in metastases compared 
to primary tumours. In tumour cells, silencing Aven triggered a G2 cell cycle arrest. Chk1 
protein levels were attenuated and ATR-Chk1 DNA damage response signaling in response to 
chemotherapy was abolished in Aven-depleted osteosarcoma cells while ATM, Chk2, and 
p53 activation remained intact. It is not possible to target Aven, therefore I examined 
whether pharmacological inhibition of the Aven-controlled ATR-Chk1 response could 
sensitize osteosarcoma cells to doxorubicin. For this purpose, I tested pharmacological 
inhibitors targeting Chk1/Chk2 or selectively Chk1 in 2D and 3D cultures. Co-treatments in 
both culture systems led to effective sensitization to chemotherapy. Together, these findings 
implicate Aven in ATR-Chk1 signaling and point towards Chk1 inhibition as a strategy to 
sensitize human osteosarcomas to chemotherapy.  
An siRNA screen targeting members of the Bcl-2 family in human osteosarcoma cell 
lines to identify critical regulators of osteosarcoma cell survival was performed in chapter 3. 
Silencing the anti-apoptotic family member Bcl-xL but also the pro-apoptotic member Bak 
caused loss of viability. Loss of Bak impaired cell cycle progression and triggered autophagy. 
Instead, silencing Bcl-xL induced apoptotic cell death. Clinical osteosarcoma samples showed 
expression of Bcl-xL, but mRNA or protein levels did not significantly correlate with therapy 
response or survival. Nevertheless, pharmacological inhibition of Bcl-xL synergistically 
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enhanced the response to the chemotherapeutic agent, doxorubicin. Indeed, in 
osteosarcoma cells strongly expressing Bcl-xL, the Bcl-xL-selective BH3 mimetic, WEHI-539 
potently enhanced apoptosis in the presence of low doses of doxorubicin. Our results 
identify Bcl-xL as a candidate drug target for sensitization to chemotherapy in patients with 
osteosarcoma.  
In Chapter 4 I performed a kinase inhibitor screen in two osteosarcoma cell lines, 
which identified MEK1/2 inhibitors: Trametinib, AZD8330 and TAK-733. These inhibitors 
were further validated in a panel of six osteosarcoma cell lines of which three were sensitive 
and three resistant to these inhibitors. Western blot analysis revealed that sensitive lines 
had high constitutive ERK activity. Furthermore, experiments in which the cell lines were 
cultured in a 3D culture system and exposed to the inhibitors, validated the effect seen in 2D 
monolayer cultures. A gene expression analysis was performed to identify differentially 
expressed gene signatures in sensitive and resistant cell lines, and indicated an activation of 
the AKT signaling network in the resistant cell lines. In conclusion, MEK1/2 inhibition 
represents a candidate treatment strategy for osteosarcomas displaying high MEK activity as 
determined by ERK phosphorylation status. 
Chapter 5, focuses on elucidating the effect of three Src inhibitors, dasatinib, 
bosutinib and saracatinib, on osteosarcoma viability and cell migration using 2D cultures and 
validation in 3D culture systems. Expression and activity of the Src cytoplasmic tyrosine 
kinase has been correlated with clinical stage and survival. All inhibitors were tested in 
combination with doxorubicin showing a reduction of the IC50 of this chemotherapeutic. 
However, only dasatinib treatment triggered caspase3/7 activation, and decreased Src 
activity. The effects of the inhibitors were studied in 3D extracellular matrix (ECM) scaffolds. 
Under these conditions, all three inhibitors reduced viability but formation of branched 
networks in 3D cultures was selectively inhibited by dasatinib in presence of doxorubicin. 
The activity of focal adhesion kinase (FAK), a Src substrate that is important for cell 
migration, was exclusively sensitive to dasatinib. Additionally, in 3D ECM-embedded 
spheroid cultures dasatinib blocked cell migration capacity whereas the other inhibitors had 
no or partial effects. Together, these findings point to the use of dasatinib as a candidate 
drug to enhance apoptosis in response to chemotherapy and to reduce metastatic spread in 
patients with osteosarcoma. 
In summary, the work presented in this thesis provides four new candidate 
treatment options for osteosarcoma. These studies provide the basis to continue this 





Osteosarcoom: de zoektocht naar nieuwe behandelingen 
 
Osteosarcoom is de meest voorkomende hooggradige primaire kwaardaardige bot tumor. 
De tumor ontstaat waarschijnlijk uit mesenchymale stamcellen die de mogelijkheid hebben 
tot vorming van botweefsel. De incidentie is jaarlijks drie gevallen op één miljoen mensen, 
voornamelijk kinderen, adolescenten en mensen ouder dan 50 jaar. 
Op dit moment bestaat de behandeling uit pre-operatieve chemotherapie gevolgd door 
chirurgische verwijdering van de tumor. De meest effectieve chemotherapeutica die 
systemisch werken zijn cisplatine, doxorubicine en methotrexaat. Ondanks intensieve 
studies naar de optimale strategie om chemotherapeutica te combineren, zijn de algemene 
vijfjaarsoverlevingskansen niet boven de 70% gestegen. Daarbij hebben 30-45% van de 
patiënten tumoren die niet reageren op chemotherapie. 
Het doel van deze thesis was om nieuwe therapeutische opties voor osteosarcoom 
patienten te ontdekken. Ik heb me daarbij gericht op het vinden van mogelijke genen en 
farmaceutische remmers die humane osteosarcoom cellen kunnen doden of gevoeliger 
maken voor doxorubicine. 
In Hoofdstuk 2 heb ik Aven bestudeerd, een adapter eiwit waarvan gedacht wordt 
dat het een rol speelt in anti-apoptotische signalering en DNA schade respons. De expressie 
van Aven is omgekeerd gecorreleerd met metastasevrije overleving in osteosarcoom 
patiënten, en is verhoogd in metastases vergeleken met primaire tumoren. In tumorcellen 
induceert het uitschakelen van Aven een G2 celcyclus arrest. De hoeveelheid Chk1 eiwit is 
verlaagd en na chemotherapie  en het uitschakelen van Aven was de ATR-Chk1 DNA schade 
respons volledig verdwenen. Dit terwijl  de activering van ATM, Chk2 en p53 intact bleef. 
Omdat het niet mogelijk is om de functie van Aven te remmen, heb ik onderzocht of 
farmacologische remming van de Aven-gecontroleerde  ATR-Chk1 respons osteosarcoom 
cellen gevoeliger kon maken voor doxorubicine. Om dit te bereiken heb ik in 2D en 3D 
kweeksystemen farmacologische remmers getest die zich richten op de functie van 
Chk1/Chk2 of selectief zijn voor Chk1. Gelijktijdige behandeling in beide kweeksystemen 
leidde tot effectieve sensitivering voor chemotherapie. Gezamenlijk impliceren deze 
vindingen dat Aven een rol speelt in ATR-Chk1 signalering en wijzen naar inhibitie van Chk1 





Om essentiële regulatoren van cel overleving te identificeren heb ik een siRNA screen 
uitgevoerd, die zich richtte op de Bcl2 eiwitfamilie, in Hoofdstuk 3. Het uitschakelen van het 
anti-apoptotische eiwit Bcl-xL, maar ook het uitschakelen van het pro-apoptotische eiwit Bak 
zorgde voor minder levensvatbaarheid van de cellen. Het uitschakelen van Bak blokkeerde 
het proces van de celcyclus en induceerde autofagie. Daarentegen induceerde het 
uitschakelen van Bcl-xL apoptotische celdood. Klinische osteosarcoom samples lieten 
expressie van Bcl-xL zien, maar de hoeveelheid mRNA of eiwit correleerde niet significant 
met de respons op therapie of overlevingskans. Desalniettemin, farmaceutische inhibitie van 
Bcl-xL verhoogt op een synergistische manier de respons op doxorubicine. Inderdaad, in 
osteosarcoma cellen met sterke expressie van Bcl-xL, verhoogde een selective Bcl-xL BH3 
mimetic (WEHI-539) in combinatie met lage doses doxorubicine apoptose sterk. Deze 
resultaten identificeren Bcl-xL als kandidaat target gen voor nieuwe medicijnen, die in 
combinatietherapie de osteosarcoom in patienten gevoeliger zou kunnen maken voor de 
chemotherapie.  
In hoofdstuk 4 heb ik een kinase remmer screen in twee osteosarcoom cellijnen 
uitgevoerd waaruit drie MEK1/2 remmers (Trametinib, AZD8330 & TAK-733) interessant 
bleken te zijn. Deze remmers werden verder gevalideerd door gebruik te maken van zes 
osteosarcoom cellijnen, waaronder drie gevoelige cellijnen en drie ongevoelige cellijnen. 
Western Blot analyse liet zien dat met name in de gevoelige cellijnen ERK-activering 
verhoogd was. Bovendien bevestigden experimenten waarin de cellijnen in een 3D system 
werden gekweekt en vervolgens blootgesteld werden aan de remmers het effect dat 
aanvankelijk in 2D celkweek systemen werd gezien. Om verschillen in genexpressie tussen 
gevoelige en ongevoelige cellijnen te identificeren, werd een genexpressie analyse 
uitgevoerd. Daaruit bleek dat activering van de AKT signaalcascade vooral bij ongevoelige 
cellijnen voorkwam. Ten slotte, het remmen van MEK1/2 vormt een mogelijk 
behandelingstrategie bij osteosarcomen die een hoog niveau van MEK activatie  hebben, wat 
bepaald kan worden door de fosforyleringsstatus van ERK.  
Hoofdstuk 5 richt zich op de effecten van drie Src-remmers (Dasatinib, Bosutinib & 
Saracatinib) op de levensvatbaarheid en migratie van osteosarcomen in 2D, en voor validatie 
ookin 3D kweeksystemen. De expressie en activiteit van de cytoplasmatische kinase Src is 
gecorreleerd met klinische fase en overlevingskans. Alle remmers werden in combinatie met 
doxorubicine getest, wat tot een vermindering van de IC50 voor doxorubicine leidde. 
Desalniettemin, alleen behandeling met dasatinib leidde tot activatie van caspase3/7 en 
verminderde activering van Src. In 3D extracellulaire matrix (ECM) kweeksystemen 
verhinderden alledrie de remmers levensvatbaarheid, maar het vormen van netwerken van 
vertakkingen werd uitsluitend geremd door dasatinib in combinatie met doxorubicine. De 
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activiteit van focal adhesion kinase (FAK), een substraat van Src dat belangrijk is voor 
celmigratie, toonde uitsluitend gevoeligheid voor dasatinib. Daarbovenop werd celmigratie 
in 3D ECM-ingebedde sferoïde kweeksystemen alleen geremd door dasatinib terwijl de 
andere remmers er geen of alleen gedeeltelijk effect op hadden. Als geheel wijzen deze 
resultaten erop dat dasatinib ertoe in staat is om apoptose in combinatie met 
chemotherapie te verhogen en wellicht metastatische verspreiding in osteosarcoom 
patiënten te verhinderen.   
Samengevat, het hier beschreven onderzoek heeft vier potentiele mogelijkheden 
voor de behandeling van osteosarcoom opgeleverd. Deze studies vormen de basis voor 
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